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Chapter 1 
INTT\ODUCTION 
111r0og!1 the years·' various studies (1-5) have been done regarding 
the prev2.l<•;:.t practice of adding one or mol'<O c'rugs to l'arente:ral fluids. 
The greatc1~ va-riety of ~.!rugs being ns ed intl·a·vEmously, F h1s the 
formulati')Ji of nm"·er and more complex paren·cera.l flu:i.ds, has led to an 
incTeased mvareness of potential i:1~::m~I}J2.tih.j litiE',s exi'::· .. ting het.H(!ar. drug 
and solution. necognitlon of the iHLZ.:-:!:rds of sv.ch exten!po-raneous combi-
Thes.:~ same .·;t.:u.iies clearly :3ho::J an ~r;1parent iJH.:.n:·r.~~e in the use 
of: the d.;~t:z-·so.1ution CGirbi!·ta-ti~.)n.~. !-Jolysi<G and Ravin ( l.), .re;Jorting on 
:fluids a.(~,T~nitltercd contained orw ndditive; 30~;; contain·.:-.1 ti'.'O ::..t•,Ld.i tives; 
of the J~/ fl.u.id:: .. adm.in:ist.e:.:·etl had ·in.lgs nddc,d. Dom1 (~)) .• _i.·d 1970, found 
that the: prop'Yi.."tion of IV fluid~: that had ~-.h·ugs r.~.cld0d tc th8::l inereased 
fror.1 SC' tc~ Jd;: b·c:t~·i8f::;'Jl the ye.::tl'S 10(>7 ··1970. Weust (4) 1 in ju~t.i.fyin.g 
l 
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There are certain hazards inheTent in the addition of drugs to IV 
fluids. Engle (26) described this practice as being " ... fraught with 
dangers which are not well recognized ... "due partially to the loosely 
defined rcsponsibi li ty of the person making additions to these fluids and 
partially to the ignorance that the broaching of the containe-;:·s of the IV 
fluid may alter the identity, strength, purity, sterility, and toxicity 
of the final product. He lists these hazards as: breakdown of sterility, 
drug compatibility, incidence of thrombophlebitis, drug availability, 
particulate matter, hospital medication error problem, and adverse 
reactions to drugs. 
In considering drug compatibility, several of the above factors 
may need to be taken into consideration, but it is not within the scope 
of this study to includ-o all the factors discussed by Engel. The 
objective of this report is to determine compatibility ch~ractcrist:\cs 
of admixtures prepared from a series of balanced intravenm.,s cJ.ectrolyte 
solutions and a group of commonly used therapeutic agents. Visual, 
spectrophotometric and microbiological assay techniques are to be used to 
establish the compatibility profiles of these admixtures. 
Developmen_t of Parenteral_ Theraer. 
The beginnings of parenteral therapy revolved around the initial 
work of Sir Christopher Wren. He sc\ccessfully attempted intravenous 
injections of medications into dogs, thus becoming the first to use the 
paronte1'<'il routo for administration of medicirnents (6). However, this 
did not mark the first time the IV route had been used; for in 1665, 
Samuel Pepys described an experiment of a blood transfusion on a human 
subject with some degree of succ.ess. !Vork with transfusions was further 
3 
carried on by Blundzll in the 1820 ' s. Blundell is credited with ext ensive 
work in transfusing blood and making the infusion technique familiar to 
the other members of his profession (7). It was in 1832 that Latta, 
working frolfi information on cholera victims, infused a solution of sodium 
chloride and sodium c~:;.rbonate . The effects, as described by Latta, were , . 
r emarkable, but limited (8). Little was knowr1 about rate::; of adminis-
tration and the correct therapeutic amounts to he adminis t ered. 
O'Shaughnessy, working with blood samples of cholera victims, att empted 
chemical analysis of blood . The results were crude, at best, but led to 
the development of a workable solution f or the treatment of cholera. 
Wren , Blundell, O'Shaughnessy, and Latta can be given credit for the 
start of IV therapy . 
The number of different par ent eral fluids availabl e tcday is 
s taggering . Minor differences do exist bet\\'ec:n eac!1 soJution, yet e~ch 
can be enclosed in three categories: Sa l ine, dextrose in t'later, and 
balanced e l ectrolyte solutions . The differences existing between each 
may be as significant as a difference in cons tituents, or may be as 
simple as a difference i n concentration of the same cons tituents . As 
knowledge of man' s internal envi nmment gTew, newer and mor e complex 
paTenteral solutions Here developed, in order to r estore or maintain i ts 
delicat e balance. The simple solution gave way to the newer, more 
physiologi cal, solutions . Finally, the admixture of parent eral fluids 
became an important part of current therapy . 
It is difficult to say when the first saline solution was used. 
The Uni ted States Di:;p_~~:sat~El. has it firs t listed jn 1918 (10) . Its 
evo lut:ion fo llowed the discovery that \~h en inorganic sa lts were added to 
water in suffj d.ent qu.a.ntit i es to wake the solution osmotically 
4 
equivalent to blood , the phenomenon known as "laking" \'las prevented (9). 
The inorganic salt used was sodiwn chloride, and the solutions were 
called normal salt solutions , or physiological salt solution. 
In 1882, Ringer performed experiments showing that the addition 
of ~;mall amounts of calcium and potassium maintained the beat ·i.ng heart 
of a turtle longer than a physiological salt solution alone. l! e then 
sugges ted that cal cium and potass ium were essential elements in human 
blood, and maintained that they should be added to a salt solution to 
render it more physiologj.cal. Further sci entific findings led to the 
eventual refinement in the combination , and the concentration of ions. 
For example, it was found that i f the so lution were made s lightly 
alkaline, i t offered still a more favorabl e medium f or the heart. In 
1895, Locke suggested the add i t ion of dextrose in o~der to provide a food 
source for t he heart . This l ed to the development (lf Lo <.:kc·-Ringcr ' s 
So lution containing, a l ong with 0ssent ial ions , one gram of dextrose in 
100 ml of wat er (10) . Further modification l ed to th~ J evelopmcnt of 
Tyrode ' s So lution compose(l of 
Sodium chloride 0.9 Gm. 
Calcium chloride 0.024 Gm . 
Potass ium chlor ide 0 . 042 Gm. 
Sodium bicarbonate 0.02 Gm. 
Dextrose 0.1 Gm . 
Wat er 100 ml 
These firs t saline- like solutions were used for introducing l arge 
quanti ties of wate!· into t he system f ast er than could be accomplished 
through t he alimentary tract . Their usA was :i.ncJuded in cases of severe 
hemorrha?.e , surgical shock, Asiati c choler a, and ars enic or l ead 
poisoning (10) . 
As earl y as 1912, experimenta l resul ts were pub lished showing the 
5 
importance of parenteral aclm;_nistra tion of sodium chloride solutions (11) . 
Hartwell and Hoguet (11) showed that, after production of hi gh i ntestinal 
obstruction ~vi th associated vomiting, the lives of dogs could be con-
tinued indefinitely with the intravenous administration of sodium chloride 
solutions. They discovered that the loss of fluid was responsible for 
the symptoms anc! death, previously thought due to the systemic effect of 
toxins. They theorized the action of the sodiwn chloride solutions t::> be 
either a diure tic action on the kidneys, helping to eliminate the poisons, 
or a diminution in the des iccation of the tissues due to the loss of 
wate r in the vomi tus. Their wor k was followed by similar s tud-ies done by 
Orr and Haden (12), and Mciver and Gan~le (13), with much the same 
r esults . 
Many years later, after the use of sodium chloride solutions for 
par ent eral administration had become a part of nor1i1al ther apy , s tudi os 
bezan to explor e the efficiency of ·ches e conm10nly t;.:>ed solut ions . As 
early as 1924, Matas (14) noted serious drawbacks of intravenous sodium 
chlor ide as being degenerative changes in the heart, muscl e , and kidneys, 
and edema of the lungs . These observations wer e suppor t ed by Coller, 
Dick, and Maddock (15) in 1936. In their woTk, they noted that saline 
solutions had become so popular, that a t endency had developed to use 
t hem for all :J.dminis trations of intravenous fluids . Thi s presented no 
probl em to the patient 1vho was defi ci ent in sodium chlor ide . However, 
in pati ents <v:!.th adequate sodium chlor ide, the development of edema was 
not 2 11 uncommon observat i on . In surgica l pati ents receiving sodium 
chlor ide o1· Ri nger ' s solutions, 12 of 13 r etained wat er . TI1ey came to 
the conclusion that r et ention of wat er f r equently occurred with admini s-
trati.on of saline solutions intravenous ly, while no r et ention of wat er 
,. 
. 
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occurred with administration of normal disti.lled water. 
Coller and his associates (15) also made important observations 
on the use of dextrose in these solutions. They recommended that dextrose 
should be supplied to all patients receiving parenteral fluids. This 
p-cevented the breakdown of fat which, when incompletely oxidized, 
acc.umulat:cd in the form of oxybutyric and diacetic acids, resulting in 
ketosis. Also, the dc~trose provided valuable calories to the 
debilitated patient. Dextrose was included in all the solutions admin-
istered to their patients involved in the experiment. 
Studies such as the one above led to the availability of dextrose 
in water solutions. These solutions have increased in popularity and are 
today the mainstay of parenteral fluids. The British Medical Journal 
(16) noted that 
. . . intravenous therapy can be considered under t•.-w headiugs: 
first, the short-term replacement of salt and ~ ater in emergencies 
where there has been deficient i ntake or excessive 1uss; and 
secondly, the longer-term problems of maintainin~ salt , water, and 
nutritional balance in patients who must be maintained by drip for 
a period of several days or more . 
Conditions which come under the first heading, such as dehydration, are 
be s t treated by infusions of water with 5% dextrose added to raise the 
osmolality of the solution to that approximating plasma. Infusion of a 
saline solution would cause a large rise in serum sodium. 
Dextrose is added to water in concentrations of 5 or 10 percent 
to increase the osmolality of the water to that approximating plasma. 
Dextrose 5% in water yields a solution with an osmola.lity of 280 
milliosmoles which compares favorably to the 310 milliosmoles of normal 
human plasma. Once the solution is infused, the dextrose is stored as 
glycogen or fat, or metabolized to carbon di oxide, leaving solute free 
water. Thi!; \'later. can be used to cover i nsensib l e water l osses or make 
up for water deficits . The 5% dextrose solution can provi de approxi-
mately 400 cal ories and is relatively insignificant in a nut r itional 
aspect. 
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In condi t ions which come under the second heading, the long t erm 
problem of maintaining water and nutritional balance, the correct ther apy 
would be infusion of solut ions of nonnal or hypertonic saline solutions 
with a l arge per centage of dext r ose or alcohol added fo r nutrition. The 
clinical condition of the patient will dictate the exact composition of 
the fluid to be infused. 
Recognizing t he desirability of maintai ning normal concentrations 
of electrolytes and water in both plasma and tissue cells, the primary 
replacement solutions available made this goal di ff:i.cul t to achiev{) . 
Various ions were being added to the basic fluid to pmvicc a solution 
that supplied t he specifi c needs of a particular patient. This l ed to 
hazards, such as loss of s t erility, incompatibility, and errol's i n 
concentration of the f inal solution. 
In an effort to achieve the goal of more effective fluid and 
e l ectrol yte r eplacement, po l yionic solutions were developed by various 
manufactm·ers. Most of these include sodiwn , chloride , bicarbonate, 
potassium , calciwn, magnesium, and phosphate in varying concentrations. 
Also included in some are dextrose and/or alcohol. These solutions are 
referred to as balanced el ectrolyte solutions . The superiority of these 
so lutions l ies in their approximation of plasma e l ectrolyte composi tion. 
Utilization of bal anced f luids will avoid inducing acidosis , 
hyperchloremia , hypopotassemia, hypocalcemia, hypomagneesemia , and 
hyponatremia 1vhich might result following infusion of saline or dextrose 
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in water so lutions (17). Talbot et al. (18), showed po lyionic solutions 
to be superior to saline and dextrose in water solutions for nearly every 
condi tion in which there is an emergency need to expand extracellular 
fluid to maintajn blood volwne. Further, t he so lution provides a con-
siderable amount of free water to cover insensible water losses , urinary 
excretion, and r epair of hypohydration .. 
Additional advantages of balanced electrolyte solutions have 
been noted by Fox (17) . The cations, in combination with bicarbonate, 
enhance excretion of excess wat er, thus preventing l ow p l asma l evel s of 
these same catious by dilution. Also they provide prompt renal r esponse 
in restoring normal volume and composition of body fluids, and are mor e 
efficient in nonnalizing abnormalities in composition of extracellular 
fluid . Intrace llular. potassium and magnesium are ut ilized more 
efficiently 1vhen r eplaced Ni th metabo li zable anions in ext r acellular 
fluid r athe1' than in t he fonn of chlorides with dextrose and \'lat er for 
diluent . Another advantage may be that replacement of potassium in sodium 
so lutions i s safer due to the fact that sodiwn will "counteract" the 
t oxjcity of inj ected potassiwn (19). 
It s eems that in situations where l arge volumes of fluid mus t be 
administered, such as hemorrhage or severe vomiting and diarrhea, the use 
of balanced e l ectrol yte so lutions would he advantageous. The avoida.nce 
of solutions which distort the concentration of one ion without af fecting 
the conr:entrat:i.on of another ion should be of paramount importance . 
Incomnatib ili ty Studi es 
____ ::...:.;.:.;; _______ ·--··------
The earliest studies of incompatibiliti es began with the work of 
Bogash in 1955 (20) . He was the firs t to recognize the responsibil ity of 
the hospital phannacist in determining the physico-chemical compatibility 
of prescribed aclmixtu:ces. His work was directed toward providing the 
pharmacist with a quick, reliable chart which could be used to determine 
the compatibility of a combination of specific therapeutic agents. He 
studied the compatibility of several frequently prescribed parenteral 
products that wer-e added singularly, or in combination, to large volwne 
sterile solutions. His procedure consisted of adding the specific 
parenteral product to the IV solution, then checking for physical com-
patibility immediately after mixing, and again four hours later. The 
criteria for incompatibility was the presence of visible particulate 
material or color change . Bogash, realizing the limitations of his study, 
stated that it '' ... cannot be used to say categorically that there will 
be no hazard, whatever, involved in the admixture of these products to 
the solutions listed." 
Kirkland and co-workers (21), determined the compatibility of 137 
drugs in 60 di fferent pa.renteral solutions . The drug was added at the 
highest dosage l evel prescribed; the admi xtures were then observed at 1, 
6: and 12 hours. The cr.iteTia for determining incompatibility was co lor 
change , haze, and/or pred pHate. Results we1·e then published in chart 
form. 
Riffkin (22), in 1963, acknowledged that formulations of manu-
factured products are compl ex and their compatibility characteristics are 
not the sarr.o as those of the activo ingredient alone . He listed the 
causes of incompatibilities as any change iu pll, viscosity, tonicity, or 
particle size distribution, and modifications of oxidation or reduction 
conditions, .l i ght exposure, and storage t emperature . lie concluded 
changes in pH to be the most frequent cause of incoMpatibility. 
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Misgen (23), in 1965, used the presence of visible particulate 
matter as the criteria in his study in which 34 drugs were cross matched 
in small quanti ties, and observed immediately after mixing, and two hours 
later. The pH of the so lutio!1s, both before and after mixing \'/ere 
determined, as well as the pH of any incompatible admixture. Misgen 
noted that in the majority of cases, the pH of the incompatible admixture 
roughly paralleled the average pH of the two combining drugs. Misgen 
a l so remarked that if the drugs were incompatible at high concentration, 
a s imilar phenomenon might be expected to occur in more dilute solutions . 
Also in 1965, Dunworth and Kenna (24) published their results on 
the admixture of 24 drugs in dextrose 5% in water. A total of 270 unique 
pairs were tested at 0, 3, 8, and 24 hour intervals . The report included 
a list of factors which mus t be considered in eval ua~ing :their da.ta . 
These factors included that only physical incompat \.bil:i t i.es 1·rere 
determined, that onl y dextrose 5% in water \1/as used, that only one con-
centration of drug was ·used, that only one brand of each additive was 
used, that chemical, bacteriological, and physiological incompatibilities 
were not studied, and that possible incompatibilities \'lith buffers and 
preservatives \1/ere not tested . Dunworth and Kenna were quick to realize 
that the reporting of physical incompatibilities alone was not enough, 
and that the chemica 1, biological, and physiological incompat.ibili ties 
of combinations of drugs should be considered. 
Pate l and Phillips (25), in 1966, reported on the compatibility 
profile of 61 intravenous additive combinations. Preliminary s tudies 
'"ere done by 111ixing different solutions on a glass slide and observing 
under a mic roscope. The criteria for incompatjbility was precipitate 
formation as viewed under the microscope . The m:i.xtu:res \~ere t hen studi ed 
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in the appTopriate dosage form over a period of 24 hours . Patel and 
Phi llips noted t hat t he order i n ~~hich drugs were. added to t he sol ution 
might determine if the admixture was compatible or incompatible , and that 
proper mixing can usual ly be l earned onl y by experience. 
II. study done by Carlin and Perkins (26) attempted to encompass 
such factors as types of reactions taking ptace between two drugs, t he 
speed with \vhich thei:r reactions take place , and the acidic or basic 
character or the va.rious drugs tes t ed . Using available <.lata from previous 
chemical incompatibility stu.dies, they proposed a method of estimating 
the react ion rate of additives by calculating the time required for 10% 
of the drug to react. They a.lso urged hospital pharmacists to become 
more aware of chemical compatibilit ies that might exi st i n an otherwise 
cl ear solut ion . 
·111e hosp:i.t.al pharmacist nmv has a.t his disposal numerous chaTts , 
publ ished by val'ious manufac'tl;ring companies . with ,,·hid! to deteTi~inc or 
predict incompatibilities . ~!any of t hese charts are compil ations of 
existing data which have been prepared by hospital pharmacists (20-26), 
or represent original research sponsored by a pharmaceutical manufacturi ng 
company (27- 28) . 
While these charts are useful to the hospita l pharmacist , all01~ing 
quick and easy reference, there are some lindtations which exist in their 
use. F. Regis Kenna (29), in describing the "Virtues and Vulnerabilities" 
of the incumpatlbi l i ty charts, states 
Certain incompatibility charts published by pharmaceutical 
manufacturers present conflicting information in many instances . 
They also are incomplete with :respect to such i nformation as room 
temperatur e , quantity of drugs , and order of mixing . When com-
pared to the results of an independent physical compatibility 
study, there were several examples of inconsistency between the 
results of the study and the data presented in the charts . Thus, 
in addition to limitations with respect to presenting infotmation 
on chemical incompatibilities, published charts are inadequate even 
in the physical compatibility data which they purport to present. 
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There are certain problems which are associated with compatibility 
charts. Most charts publish physical incompatib-Lli ties only, based upon 
the observation of particulate matter . These charts usually print a 
"disclaimer" along with the results stating that any claim of compati-
bility is based upon physical compatibility only. No claims are made as 
to whether the admixture i s compatible with regards to chemical or 
pharmacological properties (30). Some charts may have varied results 
while reporting on the same admixture. Such inconsistencies may be due 
to the brand of product, specific formulation, concentration, order of 
mixing, and period .of storage . 
Other problems 1'/ith charts occur when drugs are listed by theil· 
non-proprietary name and not their trade name. Such dnJgs may contain 
certain ingredients added for stability . Also for.rJUl<J.tion s :nay vary from 
manufacturer to manufacturer. In certain instances, it i s the added 
ingredients that react \vi th other substances to create incompatibilities. 
Inversely, problems may arise when drugs are listed by manufacturers' 
brand name. The manufacturer may change the formulation of its product, 
adding or deleting certain reactive substances , :.md changing the 
compatibility profile of.: ~thnt · d1·u~ . (?8:).. 
OthcT listings do not make mention of the concentration of the 
drug in solution. Certain drugs may be compatjble in lower concentra-
tions, yet are incompatible at the higher concentrations . Also the order 
of mixing of admixtures can affect the compatibility of several drugs in 
solution (26). 
Given no additional information, it would indeed be difficult for 
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the hospital pharmacist to evaluate the data presented in chart form. 
Since it i s his responsibility to make a professional evaluation and then 
act accordingly, these tools of evaluation should be made availabl e. 
Incompatibilities 
An incompatibility may be defined as an undesi r ab l e reaction 
between one or more drugs or the so l ution containing them. Before 
speaking furthe1· on incompa ti bi li ties of admixtures, it becomes necessary 
to define the different types of incompatibilities. Three types of 
incompatibilities can be seen in IV fluids; therapeutic, chemical, and 
physical incompatibilities. Although each is a different type of 
incompatibility, they have almost become synonymous with each other. 
Furthermore, t hese physica l and chemical incompatibi.li ties are usually of 
marked t herapeutic signi ficanc:e, thu~ becoming a th .z: rapeut:i.c incompc;ti-
bili ty. Indeed, t here is a fine line between each . 
The!_~eutic incompatibilities_. Therapeutic incompatibilities may 
occur whenever physical or chemical incompatibilities exist . Since the 
physical or chemi cal nat ure of the drug has been compromised, so may be 
the therapeutic nature, or biological response to that drug . The 
therapeutic incompatibi l ity occurs when two drugs are given concurrently 
j'.• ~ 
or so close together that t heU· : cf.f""Cct~; ove1·lap and an undesirable 
reaction occurs (31). Further definition by Endicott defines the thera-
peutic incompatibi lity as undesirable biological interactions between two 
or more ingredi ents which l ead to ( 1) pot entiation of the therapeutic 
effects of the i ngredients; (2) destruction of the effectiveness of one 
or more of the ingredients; or (3) production of a toxic reaction within 
the patients (30) . 
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Therapeutic incompatibilities occur by two different mechanisms . 
There may exis t a chemical or physica l interaction between the two drugs, 
thus altering or affecting t he expected biological response of that 
combination . This type of combination is then both therapeutically, 
and chemically incompatible . Al so , two drugs in combination may exhibit 
additive or antagoni stic pharmacologic actions, occurring without any 
s ignificant sign of physical or chemical incompat i bility (32). 
An ~;:xanrple of the fiTst type of therapeutic incompatibili ty can 
be demonstrated using t he combination of carbenicillin and gentamicin. 
The use of this combination has long been advocated in the treatment of 
serious Gram negative infe ctions. Recently, several studies have shown 
t his combination to be antagonistic (33- 34). As a result of experiments 
by McLaughlin and Reeves (34) it was shown that l a :rge doses of 
carbenicj llin inacti vated gentamicin when admixed ill the same bottle, 
thus beco~ning classified as a chemical and therapeutic i7lcoi;lpa.tibi lity . 
An example of the second type of ther apeutic inco1npatibi lity can 
be demonstrated using the combination of di gitalis glycosides with various 
other drugs, such as potassium excreting diuretics , reserpi ne , or cardiac 
depressants. A combi nation of digitalis g l ycosides with any of t he 
latter three drugs may be physically or chemically compatibl e, but each 
exh.ibi ts an additive or antagonistic action resulting i n a therapeutic 
incompatibility (35, 36, 37) . The chemi ca l a11d physical characteristics 
of digitalis are not changed ; only its phannacolog:i_cal actions. 
An example of both types of t herapeutic incompat ibil ity can be 
seen in the combination of penici llin and t et.racycli lle . The two drugs , 
when mixed in a sui t abl e diluent such as dextrose 5% in water, result in 
t he inactivation and degradation of the penicillin content, due mainl y to 
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the pH of the mixture (38). Also t et racyc line antagonizes t he effect o f 
the penicillin, reportedly by alteri ng the bacterial population , making 
them l ess susceptible to penicillin attack (39). Hence, the two drugs 
are ther apeutically incompatible due to physica l inactivation and 
phar macological antagonism. 
It i s easy to see why ther apeutic incompatibiliti es have been a 
matter of increasing concern . If the admixture is physically compatible, 
there will be no vi sual aid by whi ch to warn the pharmacist that a 
therapeutic incompatibility exi s ts . The on l y preventative of such an 
occur r ence is previous kn01v l edge of exi sting incompatibi lity. This f act 
alone necessitates further, more extensive research and reporting, and an 
increasing concern by the hospital pharmacist . 
~~~ysic~_!_ inc~npatibilitic~ . Physical incor::patibUit i es occur 
whenever a reaction occurs in a parenteral admi xture v:h.i. ch can b~ oose ~~ved 
visually. Thi s necessitat es the manifesta tion of a phys.i.~..:al change, such 
as precipitate formation , color change , or haze formation, detectable by 
the naked eye. Endicott (30) defines t he term physical incompat ibility 
as misleading and states t hat it has come to mean '' . . . a physica l or 
chemical interaction bet\veen two or more ingredients which l eads t o a 
visible change i n the mixture which can he readily observed . " Indeed, 
the formation of a precipitat e or a co l or change denotes a chemical 
interaction. 
Physh:a l i ncompatibilities were the f i rst to be reported , due 
probably to the visua l signs manifested by this type . Bogash was t he 
first to compile and report on physical incompatibilities of sel ected 
drugs back in 1955 (20). Since t hen, several studies ( 20~ ~4) have been 
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done using the parameter of visual change only. These studies l ed t o t he 
fonnulation of incompatibility charts based on physical incompatibilities 
only, circumventing chemical and therapeutic considerations. This fact 
is understandab l e since physical signs are so easily detectable \~hile 
determinat ion of chemical or therapeutic incompahbilities is difficult, 
at best, and sometimes unreliable (5). 
Determination of therapeutic and chemical incompatibilities has 
become more i n1portant due to the increasing use of parentera l admixtures 
and the incr easing potency and molecular compl exi t y of the drugs being 
used (30). Prescribing habits di ctat e the neod for more in-depth 
stability studies by the manufacturer, and further incompatibility 
s tudies by the hospi t al pharmacist. Physical incompatibi lities alone can 
no longer refl ect the complete m~ture of a drug in !' O.lut:l.on , 
_Cll~~ica~ inc~11p atibi li ties_. Chemical incorr.p<tt:ib U i t i es by our 
definition , unlike physical incompatibilities, have no vis ual evidence 
with which to detect the presence of an interaction . This difference has 
been suggested to be due t o the solubility of t he end products of the 
reaction , the by-products of chemical incompatibilities being solubl e and 
therefore invisible (40). Chemical incompatibilities present a much more 
serious problem, due to the increased chances of a chemically incompatib le 
admixture bei ng adminis t ered unknol'lingly. The i ncreas ed concern in th:i.s 
a r ea has necessi tat eel further stutly of chemi cal incompatibiliti es in 
othen~ise physically compatible o.clm.btures . 
A chemi cal i ncompatibility \: an be defjnecl as an i nteraction 
between two or more drugs \vhich dof:'s not produce a visual change, and may 
be of maxked therapeutic signifi cance (29) . The diffi culty in detecting 
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i n detecting t hese incompatibilities arises from the l ack of me thods by 
lvhich analys is can be made . Knowledge of chemi s try may not be suffi cient 
when many complex chemical compounds are combined. 
Reactions which can occur in intravenous admixtures, resulting 
in inactivati on of the components are hydrolysis, decomposition , 
i somerization , auto-oxidation , and r eactions with other sol id species 
(41). These typ-es of reacti ons can be initiated by such factors as pH 
or t emperatuTe. Perrin (42 ) states t hat the solvent containing the drugs 
can provide a major i mpetus for reactivity . He lists water and glucose 
as two such so lvent s that can l ead t o hydrolysis, especially with higher 
t emperatures, and other complex reactions which can be i nitiat ed by t he 
decomposition of glucose. Further, such factors as light, additives in 
rubber, and plastic cl osures may cau c;e prob l ems by por1~1E·~t :.on, l eaeh.ing , 
sorption, chemical r eaction, or change in pi1ysic.al pTOpt:'r1:(_es . 
The existence of chemica l incompatibill ti e:> \vas re (·ogni zerl as 
far back as the first studi es of Bogash in 1955 ( 20). He stated that his 
study r elied moTe on the physical means rather than the chemical means of 
determining compatibility . Since that t ime , almost all published r eports 
on physical i ncompatibi lities have recogni zed chemi cal i nconpatibilities 
to exist , but not withi n the scope of t heir particular s tudy. Misgen 
(23) reported t he pH of a ll incompatible admixtures he encounte-red. 
Carl in and Perkins (26) studied t he mechanism of chemical renctlon and 
estimated reaction r ates , and Riffkin (22) reported changes in pH of 
admixtures as the main cause of incompatibi l ities . 
In 1957 , · Dony-Crotteux ('~ 3) reported on a chemic3.1 incompati -
bi lity study on i nactivation of antioiotics by vitamins. It ;·1~1s found 
that tetracycline , oxytetracycline. and chlortet racyc l ine l os t biologica l 
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potency when in the presence of vitamin B complex. This inactivation 
was undetectable upon visual inspection, because no appreciable color 
change, haze, or precipitate occurred . The mechanism of this inactiva-
tion was photo-oxidation caused by riboflavin. No effect was noted when 
the solutions were kept in the dark, or in a nitrogen at mosphere and i n 
the presence of sodium t hiosulfate . 
Im and La.tiolais (44) studi•)d incompatibilities between admixtures 
of penicillin and tetra<.:ycJ ine in dextrose 5% in 1vater. Spectrophoto-
metric analysis of penicillenic acid was used to detect degradation of 
penicillin and co l orimetric anaJ ysis was used to detect degradation of 
tetracycline . It was found that penicil l in was degraded in the presence 
of tetracycline hydrochloride due to its instability in acidic media . 
Parker (45), in 1966, published results on the detc:cml nat.i,':ln of 
chemical incompatibilities of various drugs in soveu diffE:Te;;.t vehicles. 
His exact method of determining incompatibility wa::: done by ass<lying the 
drug at different inte1·vals after admixture. The 1aethod of assay was 
not specified by Parker, but was clahned to be of the stability-type 
chemi cal, or biological assay. Results were correlated with the pH of the 
solutions, as it appeared to be the dominant factor in the observed 
degradations. 
Gallelli (46) did a study of chemical compatibilities on six 
different drugs, i ncluding three ant i biotics. The solutions used as 
vehicles were either sodiwn chloride 0 .9% or dextrose 5% in water . 
Sample s were assayed chemically and microbiologically at various inter-
vals using ::1 spectrophotometer for chemical analysis and an acceptable 
microbiological assay technique. Again, in this study, as in others, the 
pH of the admixture was a determinant as to whether the drug was 
compatible. An attempt was made to correlate these findings with those 
listed by the manufacturers concerning stability in infusion fluids . 
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Ho and Geoman (47) attempted to predict theoretically the 
stability of parenteral admixtures, using chemical kinetic data. They 
asserted that the prediction of incompatibilities was possible by 
obtaining information from various research papers on the kinetics of 
certain drugs and calculating their stability profile. Several examples 
were worked out and compared to chemical compatibility data already 
available. This technique was also used by Carlin and Perkins (26) in 
their prediction of parenteral stability. 
Since determination of chemical incompatibilities is being carried 
out by many researchers, it is important to be able to analyze the 
various techniques employed by these researchers to dc!!ennine th<s· vaUdi.ty 
of da ta shown. Assay techniques may be inadequa t e and n;:,t .ce fl ec.t the 
true picture of a drug in solution . Garrett ( 48) :; t ates tlwt the validity 
of an assay may be defined as its ability to measure that which it is 
supposed to measure. When biological assays are necessary, it is fre-
quent ly assumed that degradation products of the drug do not demonstrate 
potency under the conditions of assay. It may be poss ible that the 
degradation prod~cts of a drug may gi ve anomalous results of potency when 
assayed chemically without having the same pharmacol.ogi.cal. properties . 
Chapter 2 
EXPERIMENTAL METHOD 
From the preceding discussion, it appears that balanced electro-
lyte solutions should be supel'.loT to dextrose 5% in water and normal 
saline in parenteral fluid therapy. Because it has been shown that other 
drugs ntay be <!llded extemporaneous l y, it is imp:;\rative that the 
compatibility of such admixtures be examined. 
This study was designed to explore the compatibility of two 
series of balanced electrolyte solutions with a selected group of commonly 
used therapeutic agents. To evaluate the compatibility of these admix-
tures, a combination of physica1, spectrophotometr :i.c, :md mi<>robiological 
assay techniques were employed. 
The balanced electrolyte solutions employed in this study 
included : 
Polysal 
Polysal D-5 
Polysal D-5 M 
Polysal D-10 M 
Polyenic Rl48 
Polyenic D- 5 Rl48 
Polyenic D-5 MS6 
Polyenic M900 a 
The ingredi ents a!1cl their concentrations in each fluid a1·e shown in 
Table 1. 
Addi U.·.;es \vhich were included in this study were: 
8 Cutter Laboratories, Inc., Berkeley, Calif. 
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Aminophylline 
Heparin Sodium 
Hydrocortisone Sodium Succinate 
Potassium Chloride 
Metaraminol Bitartrate 
Methylprednisolone Sodium Succinate 
Sodium Pentobarbital 
Sodium Bicarbonate 
Vitamin B Complex with C 
Trimethaphan Camsylate 
Potassium Penicillin G 
Sodium Ampicillin 
Tetracyclin:; Ilydrochloridc 
Sodium Cepha lothin 
Carb enicill i n Dis odium 
Sodiwn Cefazolin 
Ther apeut i c concentrations examined are indicated i n Table 2. 
Each drug was recons ti t uted accor ding to the manufactur er's 
directions , using st erile distill ed wat er. The drug \vas t hen added to 
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the IV fluid in concentrations Tecommended by the manufacturer . To f acil-
itate ease of storing and handling of the solutions during t he tes ting 
procedure , three aliquots of 100 ml each of the IV fluid wer e t aken and 
the drug was then added in the appropri ate concentration . 
TI1e samples were s tored at r oom t emper ature and under exis ting 
li'ghting conditions . This s i mulat es the conditions whi ch the admixtures 
would encounter in actual use. 
N 
N 
TABLE 2 
GENERIC NAME , TRADE NAME , MANUFACTURER AND THERAPEUTIC 
CONCENTRATION OF DRUGS STUDIED 
Drug 
.i\MINOl'RYLLINE 
M ETARlu'1INOL BITARTRATE 
TRIMETHAPHAN CAMSYJ~TE 
HYDROCORTISONE SODIUM 
SUCC I NL\TE 
METHYLPREDNISOLONE SODIUM 
SUCCINATE 
POTASSn~:·t CHLORIDE 
SODI UH H I•:PA1nN 
SODIUM BICARBONATE 
SODIUM rENTOBARBITXL 
VITAMIN B. CCN"PLEX 
h'ITH C 
POTASSim.f PENICILLHl G 
SODIUM AHYCC ILLIN 
SODU1 C Et-'l!ALOTHIN 
TE-TRACYCLI NE HYDROCHLORIDE 
CARBENICILLIN DISODIUM 
C EFAZOLI N SODiffi·1 
Trade Name 
Manufacturer 
.AMINOPHYLLINE INJ o , c . so 
AR/I.NINE INJ., M., S oD o 
ARFONAD , ROCHE 
SOLU - CORTEF , UP JOHN 
SOLU-MEDROL, UPJOHN 
POTASSIUM CHLO!UDt: .TNJ . , 
LILLY 
SODIUM HEPARIN INJ , , 
I NV EN EX 
SODIUM BICARBONATE INJ., 
ABBO'IT 
NEMBUTAL, ABBOTT 
SOLU B WITH C, UP JOHN 
POTASSIUM P ~'NICILLIN G 9 
LILLY 
TOTACILLIN-N, 
J3 EECHAt'1-MAS SING ILL 
KEF LIN, LILLY 
ACHROHYCIN , LEDERLE 
G EOPEN , ROERIG 
ANC EF, S oK . &F o 
SEARLE 
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Cone . 
' .. 
Oo5mg/ml 
Oo 2mg/ml 
1. Omg/rnl 
l.Omg /ml 
O.l25mg/ml 
0 . 04mEq/ml 
~~ OU / rn l 
0.05mEq/ml 
0 . Smg/ml 
5ml/L 
1(10, OOOTJ/n l 
2, Ol~:g hnJ 
Oo5mg/:nl 
l.Omg /m l 
l.Omg /ml 
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Physical Ana_.!Y.sis 
Each admixture underwent physical examination at 0, 4, and 12 hour 
intervals. The physical examination consisted of visual observation and 
pH detennination . The admixtures were closely observed against a light 
and dark background for any visual signs of incompatibility ::;uch as 
precipitate, color change, haze, or gas evolution . 
The pl-1 of the admixtures were taken at each interval us ing a 
Corning Model 7 pH meter.a Each admixture was sampled three times at 
each time interval. 
Chemical Analysis 
Ultraviolet spectroscopy. Chemical compatibilities were deter-
mined using ultraviolet spectrophotometric ana.lysis of the dnrt~ in: 
combination with the IV fluid. Any change in the l!V spec t.rog rain of th ~.t 
drug from a standard spectrogram was interpreted as an al tc-r<J.ti '.)ll in 
chemical configuration~ and the admixture \~as listed as incompatible. 
The t echnique used was a slight modification of tha t which was 
developed by Catania and King (40). A Bausch and Lomb Spectronic 600 
Double Beam Spectrophotometcrb was utilized for obtaining the spectro-
grams . A deuterium light source provided the e lectromagnetic beam in the 
wavelength range of 220 to 350 nm. Recordings of the spectra were 
obtained using a Linear/Log Varicord 43 Recorder.c Samples of the 
acorning Scientific Instruments, Cambridge, Mass. 
bBausch & Lomb Optical Co., Rochester , N.Y . 
cPhatov0lt Corp., New York, N.Y. 
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solutions were placed in Col eman 30- 300 Silica Cuvettcsa for !: canning . 
A preliminary study \vas conduc t ed in order to obtain the spectra·· 
gram of the drug in distilled \'la ter for use as a standard. Comparisons 
wer e made between the drug in the admix ture and t hese standard 
spectrograms to dete rmine if any change were manifested. Several samp l es 
of the dmg in ster ile distilled water were prepared at varying concen-
trations. These sampl es we:re th8n scanned to d.~l:e-rm.ine the opti mum 
concentration for spectrophotometric analysis . The op timuil concentration 
\vas one in which the drug demons trated an absorbance range be tHe en 0. 2 
and 1.0. These values obtained were then used t o plot 13 eer 1 s laH curves 
for each drug. 
The optimum coneentration for scanning was u sua lly (.;> ;;siderably 
less than the therapeutic concentration used in th (: tests . The.:rofore , 
diluti ons Nere made at each time interval for car.:h sample, us ing 
vo l umetric flasks and pipets . The flui d used for dilution l''<ts the s ame 
as was contained in each sample. Once the di l utions were made , the 
samples were immediately scanned. 
At test time, the admixtures 1-Jere prepared using the appropria te 
drug at therapeutic concentrati on. Then and 0, 4, and 12 hour time 
intervals, dilutions t o 25 mls were made to obtain the correct concen-
tration as determined in the preliminary s tudy . Spectrograms were 
obtained for each admixture samp l e , the reference so l ution containing the 
sa:ne paren teral :fluid but without the drug. 
Micr~]:>i_ological assar,. All t he antibiotics t es ted \vere subj ec ted 
aColeman Instruments ~ Di v . , iJerkin-Elmer Corp . , Maywoocl , Ill. 
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to microbiological analysis for determir.ution of any loss of potency. 
Under the proper concH tions, an antibiotic is capable of inhibiting the 
growth of microm~ganisms. The amount of inhibition should be related to 
the potency of the antibiotic, which can then be related to the actual 
concentration of the antibiotic. Therefore, any loss in potency of an 
antibiotic ln solution should manifest itse lf as a decrease in the 
inhibi to:cy properties of that antibiotic. 
The procedure, as outlined in the USP XVI I, was modi fied by the 
methods of Bauer, Kirby, Sherris, and Turck (49). Instead of using agar 
cups, sterile absorbent p2.per discs, a one-half inch :in diameter, were 
used. The test organism, St<~_y_!_oc~_c:cus aureus, _!~_._I_ . C.~.?~_?_93, \v a.s grovm 
and maintained on agar slants of Bacto Antibiotic Medium lf1. 0 These \ 'iel'e 
cultured for 24 hours at 3'7 degrees C. , and then -r.efTig-eratF·Jd. A ne\'1 
slant was prepared r;nce a •.veck. 
T\v enty-· four hours prior to the time of a~ say, a si.ngl e loopful of 
the t est organism was transferred to 25 mJ.s 0f Ti.Ut :d . ent b:coth , Bacto 
Antibiotic ~1edium lf2,b which had b een previou s ly sterilized a.nd stored in 
sterile 50 ml flasks. The inoculated broth \vas incubated at :-;7 degrees 
C. f or 24 hours. 
Agar plates were prepared prlor to the assay, using Bacto 
Antibiotic Medit.Eii ltl .b Work ing undc~c n laminar air-flov1 hood, 25 mls of 
tne ste6 l ::' agar wa:> .roursd into sterili:' disposable Kimblec 100 x lSnm1 
pL1!:~~ic lWtTi di s hes. Thes ~~ \Jere then stored in a refrigerator until 
a8('hle~.cher a:Hl Schuell, Inc., Keene, N.H. 
bD.f" I 1 • 1 1 .co ,aooTat.or1es, Detroit, Mich. 
cKimble Products, Div., Owens-Illinois, Toledo, Ohio. 
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one hour prior to assay. 
Immediately before the procedure began, the sterile nutrient agar 
plates were inoculated with 0.1 ml of the broth containing the 
Staphylococcus aureus. This was spread evenly on the surface using an 
L-shaped glass rod which had been previously sterilized. The inoculwn 
was then allowed to dry . Once dry, five steril e paper discs \vere p l aced 
equidist an t on the agar surface. The solutions to be tested were diluted 
to the correct pre - determined concentration, and 50 l ambdas were spotted 
onto the disc surface, using Corni ng Glass Disposable Mio·o-Sampl ing 
Pipets.a 
The therapeutic concentration of the ant i bi oti c in t he mixtm·e 
produced zon es of inhibition too l arge for measurement. For t his r·eason, 
dilution to l esser concentrations were required. To detea:!ninc optil:m:n 
test concentrations, five different so lutions of varying co:ncen.t1·ati on 
were prepared using the antibiotic i n s t erile distilled wate r . 'fhese 
were tested, following· the proc;;dure outlined above . 
At tes t time , 100 ml a liquots were prepared of each par enteral 
fluid with the antibioti c in therapeutic concentr::it.ion . These concen·· 
t ration s were determined from the manufacturers' reco~nendations. 
Finally, at 1, 4, and 12 hours, dilutions were made to produce the 
correct assay cor;centration us i ng i.:1:·.,~ · appropriate parent eral fluid. 
These sampl e s 1vere spot ted on the absorbent discs. 
To serve as contro l s, the antibiotic in stcx:i lc distilled water 
was prepared, at the correct concentration, anJ spot t ed on discs along 
with the other solutions. Also , the parenteral fluid a 1(11l 0 was used as 
a l Corning Glass Wor cs, Con1ing, N.Y. 
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a control to determine if the infus j on fluids had adde·d to the zone of 
inhibition . 
Chapter 3 
EXPERI MENTAL RESULTS 
~hysi_<:al -~ ~ilit.L..B_esult~ 
Three samples of each admixture were prepar ed using the concen-
trations listed in Table 2. Each sample was observed for any physical 
change 0, 4, and 12 hours after admixture. Phys ical changes which would 
indicate incompatibility :include precipit ation, haze, color change, 
and/or gas evo lution. The pH of the sampl es was a l s o taken at the 0, 
4, and 12 hour interval s . A significant alteration in pH might a l so 
suggest an i ncompatibi lity. 
The pH and phy~;ica l cha:t·acteristics of the t he:r-apeutic a~e1~ts in 
combi nation v1i th each of t he balanced e l ectrolyte :;:,elutions appea:c in 
Tabl es 4 through 19. The pH of the bal anced e l ect rolyte solution~ alone 
never varied and i s r eported in Tabl e 3. 
Only three of the admixtures studi ed showed signs of physical 
i!)compatibili ty. Both hydrocortisone and methylpredni sol one formed 
Ja·cc:Lpitates in Pol ym1ic M9 00 (Tabl es 5 and 6) . The milky precipitate 
:Cm·me:d i W'ledl.atcly upon aclditi on of the drug to the fluid lasted 
thT~)ughout the observation period . Sodilun Bi carbonate , a l so upon a(!di t icn 
to FoJ. yunic M900, shO\ved s igns of incompatibility i n the fonn of effer-
vesc~Hce (Table 10) . Bubbl es were fo rmed on the side of t he container at 
0, 4, ~li :Ll J.2 hours after admixture . All other admi xtures remained c l ear 
;:md co l orle->s throughout t he tes t procedure , indicating physical 
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compatibility. 
Except for the combination of sodium bicarbonate and Polyon.ic 
M900, pH changes in all other admixtures ·were insignificant. Refer to 
Tables 4 through 19. 
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TABT.E 3 
pH OF BAIANCED ELECTROLYTE FLl'IDS BEl•'ORF. ADHIXTURE 
----- --·------·----- --------·-·-·------·---
Balanced Electrolyte Fluids pH 
PCLYSAL 5.8a 
POLYSAL D··5 5.75 
POLYSAL D··5 H 5.6 
POLYSAL D··lO M 5. 55 
POLYONIC R148 7.2 
POLYONIC D-5 f..ll~8 5.7 
POLYONIC D -5 M56 5. {~5 
POLYONIC H900 
a f . 1' , mean o .. tl: ~p ~cate samp ... es 
TABLE l, 
pH and Physical Compatibility of Aminophylline 500 mg/L 
in the Balanced Electrolyte Fluids 
Test at 0, 4, and 12 Hours 
----------·-
Solution 0 Hour L~ Hour 
32 
12 Hours 
·- ------- -----·---
pH 6.45b 6.40 6.40 
POLY SAL PHYS. CHAR~ C/C . C/C C/ C 
pH 6.3 6 . 25 6 . 25 
POLYSAL D-5 PHYS . CHAR. C/C C/ C C/C 
pH 7.1 7.0 6.85 
POLYSAL D-5 M PHYS . CHAR. C/ C C/C C/C 
pH 7.1 6.8 6. 7 
POLYSAL 0··10 M PHYS. CHAR. C/C C/C (~/(! 
pH 8.7 H.7 8.75 
POLYONIC R-ll~8 PHYS. CHAR . C/C C/C C/C 
pH 6.6 6.5 6 . 35 
POLYONIC D-5 R-148 PHYS. CHAR. C/C C/C C/C 
pH 6.5 6.25 6. 25 
POLYONIC D-5 H56 FHYS . CHAR . C/C C/C C/C 
pH 4.4 { f .4 4 . 3 
POLYONIC H900 PHYS. CHA.R. C/C C/C C/C 
--------· ----- -----· 
aPhys. Char. : C/C = c lear, colorles s , no precipitate 
b mean of triplicate samples 
TABLE 5 
pH and Physical Compatibility of Hetaraminol Bitartrate 200mg/L 
in the Ba lanced Electrolyte Fluids 
Te sted at 0, 4, and 12 Hours 
Solution 0 Hour l~ Hour 12 Hours 
----- -------
pH 5.65b 5 . 65 5.65 
POLY SAL PHYS. CHAR~ C/C C/C C/C 
pH 5.6 5.65 5.65 
POLYSAL D-5 PHYS. CHAR. C/C C/C C/C 
pH 5.25 5.3 5 . 3 
POLYSAL D-5 H PHYS. CHAR. C/C C/C C/C 
pll 5.25 5.25 .5 . 3 
POLYSAL D-10 M PHYS. CHAR. C/C C/C C/C 
pH 6.0 6.0 6.0 
POLYONIC R-148 PHY S • Ctl'..AR. C/C C/C C/C 
pH 5.5 5.5 5.5 
POLYONIC D-5 R-148 PHYS. CHAR. C/C C/C C/C 
pH 5.2 5 . 2 5.2 
POLYONIC D·-5 M5 6 PHY S. CHAR. C/C C/C C/C 
pH 3.85 3.85 3.85 
POLYONIC M900 PHYS . CHAR. C/C C/C C/C 
aPhys. Char.: C/C ""' clear, color l ess > nopre cipj_tate 
bmean of t r iplicate samples 
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TABLE 6 
pH and Physical Compatibility of Hydrocortisone Sodium 
Succinate 1 Gm/L in the Balanced Electrolyte Fluids 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour lf flour 
pH " 9b :J . 5.9 
POLY SAL PHYS . CHAR~ C/C C/C 
pH 5 . 9 5.9 
POLYSAL D-5 PHYS . CHAR. C/ C CiC 
pH 5.9 5. 9 
POLYSAL D-5 H Pl-IYS. CHAR . C/C C/C 
pH 5.9 S.9 
POI.YSAL D- 10 M PHYS. CHAR. C/C C:/C 
pH 7 . 25 7 .'1.5 
POLYONIC H.-148 PHYS. CHAR. C/C C/C 
pH 5.9 5.9 
POLYONIC D- 5 R- 148 PllYS . CHAR. C/C C/C 
pH 5. 115 5 . 7 
POLYONIC D-5 M56 PHYS . CHAR. C/C C/C 
pH 4 . 35 4.4 
POLYONIC M900 PIIYS . CHAR. ppt:. ppt. 
12 Hours 
5 . 9 
C/ C 
6.0 
C/ C 
5.8 
C/C 
5, 9 
C/C 
7 . 25 
C/C 
5 . 9 
C/C 
5 . 7 
C/C 
4 .Lf 
ppt. 
aPhys. Char. : C/C = c l ear , colorless , no precipitate 
bmean of tr i plicate samples 
TABLE 7 
pH and Physical Compatibility of Methylprednisolone Sodium 
Succinate 125mg/J~ in the Balanced Electrolyte Fluids 
Teoted at 0, 4, and 12 Hours 
Solution 0 Hour 4 Hour 12 H.curs 
--·--·--··-·----~--.--..... _. _ ___ _.... __ .._ ________ .04~---·-
pP.. 6.0b 6.0 6.1 
POJ.YSAJ .. PINS. CHAR~ C/C C/C G/ C 
pH 5.95 6 . 0 6.0 
POLYSAL D-5 PHYS. CHAR . C/C C/C C/C 
pH 6.2 6.2 6.2 
POLYSAL D-5 t1 PHYS. GHAR. C/C C/C C/C 
pH 6.2 6.15 6 .l5 
'POLYSAL D··lO M PHYS. CHAR. C/C G/C C/C 
pH 7.35 7.1 6.9 
POLYONH~ R-11~8 PHYS. CIU\R. C/C CiG C/C 
pH .5.9 S.9 .5.9 
POLYONIC D-·5 R-ilf8 PIWS. CHAR. C/C C/C C/C 
pH 5.85 5 . 8 5. 8 
POLYOdiC D··S H.56 PHYS. CHAR. C/C C/C C/C 
pH Lf .5 4 .,6 4.65 
POLYONIC H900 PirlS. CIIAR. ppt. ppto ppt. 
8 Phys . Char. : C/C =clear , color le ss, no pcecipitate 
bmean of triplicate samples 
36 
TABLE 8 
pH and Physical Compat ibi.lity of Potassium Chloride 40mEq/L 
in the Balanced Electrolyte Fluids 
Tested at 0, 4, and 12 Hours 
---- - -- -------- - --
Solution 0 Hour l~ Hour 12 Hours 
-------
pH 5.75b 5.75 5 . 8 
POLY SAL PHYS. CHAR~ C/C C/C C/ C 
pH 5.8 5.75 5.75 
POLYSAL D-5 PHYS . CHAR. C/C C/C C/C 
pH 5.6 5 . 5 5 .6 
POLYSA!, D-·5 M PHYS . CHAR. C/C C/C C/C 
pH 5.5 5o.) ,. <; .) . .., 
POLYSAL D-10 H PHY'S . CHAR. C/C C/C C/C 
pH 7.2 7 .15 7. 1 
POLYONIC R-148 PHYS. CHAR. C/C G/C C/C 
pH 5.65 5. 6 5.6 
POLYONIC D-5 R-148 PHYS. CHAR. C/C C/C C/C 
pH 5.35 5 . 35 5 . 4 
POLYONIC D- 5 H56 PI-IYS. CHAR. C/C C/C C/C 
pH 3 . 95 3.95 3.95 
POLYONIC H900 PHYS, CHAR. C/C C/C C/ C 
---·- .. 
aPhys. Char .: C/C "' c l ear, color l ess, no pr~cipt tate 
b 
mean of trip lie ate samples 
TABLE 9 
pH and Physical Compatibility of Vitamin B Complex 
with C 5 ml/L in the Balanced Electrolyt e Fluids 
Tested at 0, 4 , and 12 Hours 
·~-
Solut ion 0 Hour 4 Hour 12 Hours 
pH 5.6h 5.6 5.65 
POLY SAL a C/C C/C C/C PliYS. CHAR. 
pH 5 .55 5 .55 5.55 
POLYSAL D-5 PHYS . CHAR. C/C C/C C/C 
pH 5 .1 5. 1 5. 1 
POLYSAL D-5 M PliYS. CHAR. C/C C/C C/C 
pH 5 . 1 s.J. s .J. 
POLYSAL D- 10 M PHYS. CIL.~R . · C/C C/C C/C 
pH 5 . 7 5.9 6 . 1.') 
POLYONIC R-148 PHYS. CHAR. C/C C/C C/C 
pH 5.35 5.35 5 .LI 
POLYONIC D-5 R-148 PHYS. CHAR. C/C C/C C/C 
pH 5. 1 5 . 1 5. 1 
POJ..YONIC D-5 M56 PHY S. CHAR . C/G C/C C/C 
pll 4. 0 t,. 0 3.9 
POLYONIC t-1900 PHYS. CHAR. C/C C/C C/C 
a phys. Char .: C/C = ch:a r, no precipi t a te 
bmean of triplica te samples 
TABLE 10 
pH and Phys:i.ca l Compatibility of Sod ium Bicarbonat e 50tnEq/L 
in the Ba l anced El ectrolyte Fluids 
Tested at 0, 4, and 12 Hours 
-----· 
So lution 0 Hour 4 Hour 
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12 Hours 
--- - --------
POLY SAL 
POLYSAL D-·5 
POLYSAL D-5 M 
POLYSAL D-1.0 M 
POLYONIC R- 148 
POLYONI C D--5 R- 148 
POLYONIC D-5 M56 
PO'LYONIC M900 
pH 
PHYS. CHAR~ 
pH 
PHYS . CHAR. 
pH 
PHYS. CHAR. 
pH 
PHYS. CHAR . 
pH 
PHYS. CHAR . 
pH 
PHYS . CHAR. 
pH 
PHYS. CHAR. 
pH 
PHYS . CHAR . 
7.4b 7.45 
C/C C/C 
7 . 35 7.4 
C/C C/C 
7.7 '1.7 
CiC C/C 
7 .65 7 . 65 
C/C C/C 
8.1 8.1 
C/C C/ C 
7.4 7 .45 
C/C C/C 
7.4 7 • .5 
C/C C/C 
7.1 6. 9 
Eff. Eff. 
aPhy s . Char. : C/C =clear, colorless, no precipitate 
bmean of trip licat e samples 
Eff. =effervescence 
7. t~5 
C/C 
7 . 45 
C/C 
7.7 
C/C 
7.65 
C/C 
8 . 2 
C/C 
7 . 5 
C/C 
7 . 55 
C/C 
6.8 
Ef£. 
TABLE 11 
pH and Physica l Compatibility of Sodium Heparin 20 ,000U/L 
in the Balanced El ectrolyte Fluids 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour 4 Hour 
pH 5 .85b 5. 8 
POLY SAL PHYS . CHAR~ C/C C/ C 
pH 5.8 5 . 8 
POLYSAL D-5 PHYS. CHAR. C/C C/C 
pH 5 . 6 5.6 
POLYSAL D-5 M PHYS. CHAR. C/C C/C 
pH 5.6 5. 6 
POLYSAL D-10 M PHYS. CHAR . C/C C/C: 
pH 7.2 7 . 15 
POLYONIC R -11+8 PHYS. CHAR. CiC C/C 
pH 5.7 5. 7 
POLYONIC D-5 R- 148 PINS. CHAR . C/ C C/C 
pH 5. 35 5. 35 
POLYONIC D-5 M56 PH'l S. CHAR . C/ C C/C 
pH 4.0 Lf, 0 
POLYONIC M900 PHYS . CHAR. C/C C/C 
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12 Hours 
5.8 
C/C 
5.8 
C/ C 
5. 6 
C/C 
5. 6 
C/C 
7.1 
C/C 
5 . 6 
C/ C 
5. 35 
C/C 
l f .o 
C/C 
----·----
i:l Phys. Char .: C/C =clear , col or l es s, no precipita t e 
b 
mean of t riplicate sampl es 
TABLE 12 
pH and Phy s i ca l Compatibility of Sodium Pen tobar bita l 125mg/L 
in the Ba l anced Elec trolyte Fluids 
Te s t ed a t 0, 4, and 12 Hours 
Solution 0 Hour lf Hour 
--------· 
pH 6.1 b 6 . 1 
POLY SAL PHYS. CHAR~ C/C C/C 
pH 6.1 6.1. 
POLYSAL D-5 PHYS. CHAR. C/C C/C 
pH 6.95 7.0 
POLYSAL D-5 t1 PllYS. CHAR. C/C C/C 
pH 7 . 0 7.0 
POLY&\L D- 10 H PHYS. CHAR. C/ C C/C 
pH 8. Lf 8.35 
POLYONIC R-148 PHYS. CHAR. C/C C/ C 
pH 6 . 2 6.2 
POLYONIC D-5 R-148 PHYS. CHAR. C/C C/C 
pH 5.95 5.95 
POLYONIC D-5 M56 PHYS . CHAR. C/C C/C 
pH 4.35 4.35 
POLYONIC H900 PINS. CHAR. C/ C C/C 
40 
12 Hour.s 
6.15 
C/C 
6.1 
C/ C 
7 . 0 
C/C 
'l , 0 
C/C 
8.35 
C/C 
6.2 
C/C 
5 . 95 
C/C 
4.35 
C/C 
·-----· -· -------------- -----· 
aPhys. Char.: C/ C = c l ear, c ol orless, no precipi tate 
b 
mean of triplicate samples 
TABLE 13 
pH and l?hys j cal Compa t ibility of Trime tha phan Ca.msylate 1 Gm/L · 
in the Balanced Eledro lyte Fluid s 
Tested at 0, 4 , and 12 Hours 
So lution 0 Hour 4 Hour 12 Hours 
pH 5. 8b 5.8 5.8 
POLY SAL PHYS. CHAR~ C/C C/C C/C 
pH 5.75 5.75 5. 75 
POLYSAL D-5 PtfYS. CHAR. C/C C/C C/C 
pH 5. 6 5.6 5.6 
POLYSAL D-5 M PHYS . CHAR . C/C C/C C/ C 
pH 5.6 5 . 6 .5.55 
POLYSAL D-10 H PHYS. CHAR . C/C C/C C/C 
pH 7o2 7.2 7 . 2 
POLYONIC R- 148 PHYS . CHAR. C/C C/C C/C 
pH 5 .7 50., 5. 7 
POLYONIC D-5 R-148 PlfYS . CHAR. C/C C/ C C/C 
pH s . L~s 5 .L~5 5 . L~5 
POLYONIC D-5 M56 PHYS . CHAR . C/C C/C C/C 
pH 3 . 95 3 . 95 3.95 
POLYONIC M900 PHYS . CHAR . C/C C/C C/C 
, _______ .. 
a Phys. Char . : C/C = clear, col or l ess , no precip:l tate 
brnean of triplicate samples 
TABLE 14 
p~ and Physical Compatibility of Potassium Pe nici llin G 
l,OOO,OOOU/L in the Balanced Electrolyte Fluid s 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour 4 Hour 
pH 6. lb 5.9 
POLY SAL PHYS. CHAR~ C/ C C/C 
pH 5.8 5.8 
POLYSAL D-5 Pl:IYS. CHAR. C/C C/C 
pH 5.6 5.7 
POLYSAL D-5 M PtiYS. CHAR. C/C C/C 
pH 5. 6 5o6 
POLYSAL D-10 M Pl-IY s. CHAR. C/ C C/C 
pH 7.2 7.1 
POLYONIC R-148 PHYS . CHAR . C/C C/C 
pH 5 . 7 5 . 8 
POLYONIC D··5 R-11+8 PHYS. CHAR. C/C C/ C 
pH 5.5 5.5 
POLYONIC D-5 M56 Pl-IY S. CHAR . C/C C/C 
pH Lf . 2 4.2 
POLYONIC M900 PHYS. CHAR. C/ C C/C 
-------· 
8 Phys. Char. : C/C = c l ear, colorless , no prec ipitate 
bmean of triplicate samples 
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12 Hours 
5.9 
C/C 
5.8 
C/C 
5 .7 
C/C 
5. 6 
C/C 
7 . 0 
C/ C 
5 .7 
C/C 
5.5 
C/ C 
4 . 2 
C/C 
TABLE 15 
pH and Physical Compatibility of Sodium Ampicillin 2 Gm/L 
in the Balanced El ectro lyte Fluids 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour 4 Hour 
pH 1 .ob 7.2 
POLY SAL a C/C C/C PHYS. CHAR. 
pH 7.0 7.2 
POLYSAL D··5 PHYS. CHAR. C/C C/C 
pH 6.8 6.9 
POLYSAL D-5 M PHYS. CHAR. C/C C/C 
pH 6.7 6.8 
POLYSA'L D-10 M PIIY S ~ CHAR .· C/C C/C 
pH 8.2 H. 2 
POLYONIC R-148 PHYS. CHAR. C/C C/C 
pH 7.1 7.2 
POLYONIC D-5 R-148 PRY S. CHA.."'l. C/C C/C 
pH 7.0 7.1 
POLYONIC D-5 '1-156 P}IYS. CHAR . C/C C/C 
pH I~ • 9 4.9 
POLYONIC M900 PHYS. CHAR. C/C C/C 
a C/C == c l ear, colorless, precipitate Phys. Char: . : no 
b 
of triplicate samples mean 
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12 Hours 
7.2 
C/ C 
7.2 
C/C 
6.9 
C/C 
6.8 . 
C/C 
8 .3 
C/C 
7.2 
C/C 
7.2 
C/C 
L~ o 8 
C/C 
TABLE 16 
pH and Physical Compatibility o£ Tetracycline Hydrochloride 
500mg/L in t he Balanced El ectrolyte Fluids 
Tested at 0, 4, and 12 Hours 
So lution 0 Hour 4 Hour 
pH 5.3 b 5o3 
POLY SAL PHYS. CHAR~ C/C C/C 
pH 5.3 5o3 
POLYSAL D-5 PHYSo CHAR. C/C C/C 
pH 4 0 7 4.7 
POLYSAI. D-5 M PHYSo CHAR. C/C C/C 
pH 4o7 ho7 
POLYSAL D- 10 M PHYSo CHAR. C/C C/G 
pH 5o l s r, • .:> 
POLYONIC R-148 PI-IYSo CHAR. C/C C/C 
pH 5o0 5. 1 
POLYONIC D-5 R-ll;8 PHYS . CHAR. C/C C/C 
pH 4o7 Lt .• 8 
POLYONIC D-5 M56 Pl-IY S o CHAR. C/C C/C 
pH 3.5 3o5 
POLYONIC M900 PHYS o CHAR. C/C C/C 
41; 
12 Hours 
5o3 
C/C 
5o3 
C/C 
t,. 8 
C/C 
l; < 8 
C/C 
5~3 
C/C 
5. 1 
C/C 
4.8 
C/C 
3.6 
C/C 
- --- - -·--·· 
a.Phys . Char. : C/C == clear, colorless , no precipitate 
bmean of triplicate samples 
TABLE 17 
pH and Physical Compatibility of Sodium Cephalothin ?.Gm/L 
in the Balanced Electrolyte Fluids 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour 4 Hour 
b 
pH 
a 
5.3 5,9 
POLY SAL PHYS, CHAR. C/C C/C 
pH 5.8 5.8 
POLYSAL D-5 PHYS, C!1.AR. C/C C/C 
pH 5.5 5.6 
POLYSAI. D-5 M Pl!YS. CHAR, C/C C/C 
pH 5.5. 5~5 
POLYSAI. D-10 !1 PHYS. CHAR. C/C C/C 
pH 6,2 6.3 
POLYONIC R-11+8 PHYS, CHAR. C/C C/C 
pH .5.5 5.5 
POLYotiiG D-5 R-148 PHYS. CHAR. C/C C/C 
pH 5.3 5.4 
POLYCNIC D-5 1156 PI-!Y S. ClLI\R. C/C C/C 
pH 4.0 4.0 
POLYONI.C l1900 PIIYS. CHAR, · C/C C/C 
---~·--
6
.Phys. Char o : C/C =: clear 1 colorless, no precipitate 
b mean of tt·iplicate samples 
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12 Hours 
5.9 
C/C 
5,8 
C/C 
5.6 
C/C 
5.5 
C/C 
6.3 
C/C 
5.6 
C/C 
5,4 
C/C 
4.1 
C/C 
TABLE 18 
pH and Physical Compatibility of Carbenicillin Disodium lGu1 /L 
in the Balanced Electrolyte Fluids 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour l~ Hour 
-----------·-------·------------
POLY SAL 
POLYSAL D-5 
POLYSAT., D-5 M 
POLYSAI. D-10 M 
POLYONIC R-148 
POLYONIC D-5 R-148 
POLYONIC D-5 M56 
POLYONIC t-1900 
pH 
a 
PHYS. CHAR. 
pH 
PI:IYS. CHAR. 
pH 
PHYS. CHAR. 
pH 
PHYS. CHAR. 
pH 
PliYS . CHAR. 
pH 
PRY S • CHAR o 
pi! 
PliY S. CHAR o 
pH 
PHYSo CH.AR. 
b 
6.0 
C/C 
5.8 
C/C 
5.7 
C/C 
5.6 
C/C 
7.1 
C/C 
5.8 
C/C 
5.4 
C/C 
4ol 
C/C 
5 . 7 
C/C 
5 .7 
C/C 
.'L6 
C/C 
7. 1 
C/C 
5.8 
C/C 
l~ 0 0 
C/C 
46 
12 Hours 
5.9 
C/C 
5.7 
C/C 
5.7 
C/C 
7.0 
C/C 
5.7 
C/C 
5.4 
C/C 
4.0 
C/C 
------ ----------·-------·---------·-·-·--·----
aPhys. Char.: C/C "' clear, c o lorless, no precipitate 
bmean of trip licate samp les 
)' 
TABLE 19 
pH and Physical Compatibility of Cefazolin Sodium 1 Gm/L 
in the Balanced Elecrrolyte Fluids 
Tested at 0, 4, and 12 Hours 
Solution 0 Hour 4 Hour 
b 
pH 
a 
5.3 5.4 
POLY SAL Pl-lYS. CHAR. C/C C/C 
pH 5.2 5.2 
POLYSAL D-5 PilYS. CHAR. C/C C/C 
pH 5.1 5.1 
POLYSAL D-5 M FlfYS. CHAR. C/C C/C 
pH 5.1 5.1 
POLYSAL D-10 M PHYS. CHAR. C/C C/C 
pH 6.3 6 ~'-~ 
POLYONIC R-ll.f8 l1HYS~ CHAR. C/C C/C 
pH 5.2 5.2 
POLYONIC D-S R-1.48 PHYS. CHAR. C/C C/C 
pH 4.6 lfo 7 
POLYONIC D-5 N56 PHYS. CHAR. C/C C/C 
pH 3.6 3.6 
POLYONIC M900 PIIYS. CHAR. C/C C/C 
---· ------
a •. l P. 1y s. Char.: C/C = clear, colorless, no precipitate 
b 
mean of triplicate samples 
12 Hours 
----
5 . Lf 
C/C 
5.3 
C/C 
5.1 
C/C 
5.1 
C/C 
6.4 
C/C 
5.2 
C/C 
4.7 
C/C 
3.5 
C/C 
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Chemical Com~t.ibi li t y Results 
UV~troscopy. lN spectroscopy was utilized to determine the 
chemical compatibility of a drug in solution. A UV spectrogram was 
obtained for each drug in combination with the electrolyte fluids at 0, 
4, and 12 hours. These were then compared against a standard spectrogram 
to detect any decrease in absorption or other a lteration in the IN 
spectra of that drug. A significant decrease in absorption or alteration 
of the W spectra of a drug suggested chemical incompatibility . 
Certain drugs, due to their chemical configuration, will not 
produce a UV spectra in the wavelength range of 220 to 350 run. For this 
reason, five of the non-antibiotic drugs could not be t es ted for chemical 
compatibility using this procedure. Compatibility evaluation for these 
drugs (potassium chloride, heparin, trimethaphan c:::msylate, vit <min B 
compex with C, and sodium bicarbonate) r elied on physical co1npati bility 
results alone . 
In those examined by UV spectroscopy, dilutions of the therapeutic 
concentration were necessary to produce lN spectra in the desired range. 
These dilutions appear in the legends belol'l each figure. The optimum 
dilution was determined using Beer ' s law plots for each drug (Graphs 
1-5). 
Aminophylline exhibited a A max of 2'l5 nm at a concentration of 
2o/"g/ml in all the el ectrolyte fluids except Polyonic tvl900 (Figure 2). 
In admixture with Polyonic M900, aminophylline exhibited a ~A max of 262 nm 
and a decrease in absorption, indicating incompatibility (Figure 3). 
Metaraminol bitartrate , 24.p. g/ml, produced a Amax of 273 nm 
(Fig·.JTe 5), in all so lutions excep t for Polyonic ~·1900. In Polyonic M900, 
49 
it showed a /\max of 260 run (Figure 6) and decreased absorption, 
suggesting this admixture to be incompatible. 
Sodiwn pentobarbital, at 20~g/ml, produced a standard spectro-
gram with a 'Amax of 245 nm (Figure 7). Only one of the admixtures, 
sodium pentobarbital and Polyenic Rl48, had a (\max at 245 nrn (Figure 
l.L). The other admixtures resulted in altered IJV spectra. The admixture 
with Polyonic M900 produced a {\max at 230 (Figure 8). The admixtures 
with Polysal, Polysal D-5, Polysa1 n-s M, Polysa.l D-10 M, and Polyonic 
D-5 l\156 produced a /\max at 220 nm (Figure 10) . The admixture with 
Polyenic D-5 Rl48 displayed a Amax at 220 nm (Figure 9) also, but \vith 
a consequent decrease in absorption. It \VOuld appear that, in this 
series, sodiwn pentobarbital is compatible in Polyonic RJ.48 only. 
The examination of hydrocortisone sodium sw::cinat e shm~ed a /u,J ~>..:( 
at 253 nm in all admixtures (Pigure 13) except Pol yunit:: M900 . Much t he· 
same results were produced with 1nethylprednisolone sodium succinate . 
Admixture with a ll solutions except Polyonic M900 :>roduc0d a 1\Jnax of 
251 nm (Figure 16). Admixtures of hydrocortisone and methylprednisolone 
with Po l yonic l\1900 produced a mi lky white precipitate, which i ndicated 
that spectrophotometric analysis was unnecessary. 
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0 
:'H c. .~:~~Le>lo_gi c_!:l.l assar_. Each admixture containing an antibiotic 
was as:; ayed mi c :cobiologically to determine loss of potency. The zones 
of ~.nhibition of ~_!~aphylococcus aureus produced by the admixture were 
comp .:n:ed to a standard, at 0, 4, and 12 hours. A significant increase 
or decrease in zone sizes suggested an incompatibility existed. 
Dilutions of the therapeutic concentrations had to be made to 
achieve an ·:)p timwn zone size. The se dilutions were determined in a 
pre liminary test using the drug in several different strengths. 
Statistical evaluation, to determine if a significant change in 
zone s ize had occurred, was accomplished by using the "Student T" test. 
Result::: app0ar after each set of data for the individual antibiotic. 
61 
Pot&ss ium penicillin G showed a de crease in zone size in Polyenic 
M900 at 12 hou~s (Table 22) after rem~ining stable at the 0, and 4 hour 
interval. Po t ass iu.'ll penicillin G appeared to be 5tQble i n all o ther 
solut ions th1·oughout the test p eriod, Sodium a.mpi c i.llin sh01·1ed an 
increase in zone s ize in Polyenic M900 at 0, 4, and 12 hours (Tables 
23-27), and remained stable in all o ther solutions. Tetracycl i ne hydro-
chloridr~ appeared unstable in Polyenic M9 00 at 0, 4, and 12 hou1·s (Tables 
28-·30), and unstable in Polyenic Rl48 at the 1 2 hour interval (Table 30), 
whlle re.!r.aining ·s table in all other admixtures. The stability of sodium 
cephalothin was unaltered in any of the admixtures (Tables 32--34). 
Carbenicillin disodium appeared unstable in Polyonic M900 a t 4 and 12 
hour~·. (Tables 37, 38), while exhibiting no other signs of ins tability. 
Sodium cefazolin s hmved a significant decrease in zone di ame ters in 
Polyonic M900 (Tables 40 -42), but remained stable in all other solutions. 
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• .L o I / .._, 
---------~------
Pel~ sa l 
2S .:.::. 
2:: , , 
..- . "..J 
17,9 
26.8 
251)~ 
2(-:o~ 
27.8 
2-:,.o 
2$o? 
;~ () ~ 8 
·;c r.. 
_,_, ..,. "" 
27 .4 
26_,(; 
27 c. 2 
2~ c .l 
27u26 
+lQ 3}.4 
~Standard Deviation 
Poly sa ~ 
D- 5 
/2 . :'> 
~6 :. l!-
~:3 " 4 
: .. ~ .'; 0 6 
.. I ,., 
~ ~'l. otJ 
26 .. 5 
'2"/o L 
25.8 
:~'? 0 l 
"<: A 
/ .. .. • 0 ·J 
•) ' : 
•. tl , .!. 
l ·~~ 3 
26~ ,;; 
20.,i:. 
26.0 
26o 25 
+1.261 
Po~ys~ l 
D-5 M 
1f~ ,.0 
'/7 .. . j 
25 .~ 
26 ¢3 
- -
:~.4 
'J i ' ! . 
- (50 ..,. 
26.4 
?5 . 1 
•) r: ·~ 
...... ,..; ".J 
27. G 
29 ,. 6 
29.1 
26c;8 
28o6 
27 018 
+l.396 
z ~) t!eS Df Il:'!t :.b ;_ tiot~ (!r:~t) 
~~lys~ l 
il 10 ~ 
28 . 4 
27 ~ /~ 
2 :; 0 L; 
27~2 
26o5 
28 . 2 
2.7 . 9 
28.7 
2t.4 
!.I o 0 
28.1 
27 0 L. 
26.9 
25"4 
L7o9 
': 0 ? ~ J... .-Jv - .... 
+l o 010 
Po~yo~ic 
Ri4S 
'!-· G 
"'v.-
~ 8 c3 
2~o4 
2::0 2 
~~ 9 ~, 2 
2.5 .L;. 
28.0 
~~~ t) 6 
23.1 
27 0.5 
23.5 
29~2 
27 .5 
27 0 0 
2:1. 4 
2! .58 
+L345 
Po l yenic 
Rl4E D- 5 
'20,. 7 
.... '"' ,, L <..J . ~ 
27.C 
2 ~l ~ 6 
25.6 
n .7 
2.7.2 
26u3 
23o 0 
30.0 
27.6 
'1..7. 2 
28o5 
27 0 2 
27.9 
27.69 
±1.073 
Po lyenic 
J - 5 M56 
26. 4 
28 o:.J. 
2 :~ ~ 7 
2:, 'I 
'.J .:..:.. 
:-~3 0 6 
•)t.: ~ 
,L,') . \,.. 
?7~4 
:!.7.2 
2.S.,5 
,.,,.. I"\ 
.:. Co .t. 
•')f" , 
-<.Oo'+ 
27 .s 
26.2 
27.6 
2S ~ C 
27.01 
+1.353 
Polyenic 
M900 
25o8 
26.1.3 
,..., .., r 
/... I • C 
~3o2 
2L: .. 8 
26,9 
?-:" , .. 
-! 0 v 
25.2 
.L6 . 0 
LS I) S· 
26o2 
2/o6 
25.\) 
2 ~~ 0 2 
27 . 0 
26.32 
+l ol9l 
Control 2 
.... . . c 
£/oV 
27., l~ 
2o .s 
2S ~~ 
28 . !; 
27 . 6 
27 . 0 
28 , 2 
~-,. 0 
L.C co 
?../.2 
.., ·' . 
.· .. 0 . J. 
. ... c r· 
.!. •") . •.; 
27,0 
'")/. I") 
_ ..... ,) '-
26~4 
2/u05 
• - , Q" 
T .t o.a..vl 
~ -
~..;. 
TATILZ 21 
Zor:es of }:r:hib:i.t.:on o::: Staph v J. ::;r:occ:..s c.1 : .::eus bv Potassium Pe~id.l1.in G 5000i.J/ml 
-------------- -in th;.:: B'-11 £~C(:d El e ctro 1.y~ ~ F.tuirl s 1c~r:ed L~ I!ours After A ..G.n:i~<t~lre 
c~r .. tr.J1 ~ l"'o l ys.J. l 
27<:-6 "' '" LO -.u 
·; <:; ·~ __ ,...., 27.5 
L6.:4 ....... - "\ L: • '-
27 ~ 3 27.7 
26. 8 27 . 2 
24.6 25.3 
23 . 8 2~.2 
2c , 1 26 .0 
26 .. 0 25o3 
30. 2 28.3 
2 1:~ .. 9 26.C 
'27._6 25.4 
2 1.;.. 6 L6o?. 
25 .6 2.6 .6 
25 . 0:::. 27 . 8 
------
26.55 26 . 79 
71.5 710. +-1.062 
- --· 
a 
St?..ndard Deviation 
? e l y sal 
D-5 
28.0 
25.4 
26 . 0 
27 o ~ 
2Sv 7 
27.6 
~ ... ~ /. . .J o ~ 
2 '~ I. 
-· 0~ 
,.1 _ ..... 
.:.../ >) L 
27 . 3 
---- c. ~:) 0 0 
'27o 'J. 
26.7 
27 G 2 
28.1 
26. 80 
+ .898 
Polysal 
D-5 M 
26.2 
28.0 
'2.8."1 
26.9 
26.8 
26.0 
25.5 
24 . 8 
25.7 
23 .3 
25.1 
26.t.J. 
28 .1 
26.1 
28.9 
26.43 
+1.531 
Zones of I r,hibiti0r. (mm) 
Po l y sal 
D- 10 M 
21.4 
22. 4 
23 . 2 
23.6 
21.0 
23.6 
'I-~ ' ) , , __ ... 4 
22,8 
23 .2 
22.4 
24 .0 
27 > 2 
25.4 
25 . 9 
2L: .• 8 
2") .: ~ J (,oV lJ 
Polyenic 
Rl43 
26.2 
26.9 
26o8 
27.:-1 
26 . 2 
25.0 
26o0 
23 ~~~ 
26o<J 
25,() 
23o5 
25.6 
LL:. ~2 
2-~ ,3 
23o:6 
25.42 
+1.316 
Polyonic 
Rl48 D-5 
27.4 
27o6 
26.0 
25.8 
26.0 
25.7 
26.0 
25 . 0 
26.4 
26. 7 
26.0 
29.4 
23 . 0 
23.6 
25.0 
25.97 
+1.549 
Pvlyonic 
D-5 M56 
27 0 2 
26.3 
24 o2 
26.2 
26.1 
27.2 
25.6 
27.9 
29 . 2 
26.2 
27.3 
26.8 
26.2 
23.9 
26.2 
26.43 
+1.318 
Pclyonic 
M900 
29.6 
27.4 
24.2 
25.7 
26 . 7 
26.6 
24.7 
2l~. 0 
27.4 
25.0 
2?.0 
25 . 0 
26.9 
24.6 
24.8 
25.97 
+1.557 
Contr ol 2 
27.2 
27.3 
27.6 
28.3 
28.7 
26.2 
26.1 
23.6 
24. 2 
24 . 0 
23 . 9 
25 . 0 
26e2 
26. 2 
24.0 
25.90 
+1. 704 
~j'\ 
t • ..; 
TABLE 22 
Zones of Inhibi.::ion cf ~_::aphylococc~:.s au;:-.eus by Po::.::tss i.ur.'l Penicillin G 5000U/ml 
in t he Balanced Elec-.:rclyte Flu~ds T<::si:ed 12 Hours After Admixt~:.re 
Co-z·~t"!"o l 1 Poly sa l Poly sal 
D- 5 
Poly sa~. 
D-5 Y!. 
Zone s of Inh ibition (mm) 
Pol:,sa!. 
D-10 ~ 
Polyonic 
Rl48 
------------------------------· 
29o0 
28.8 
r u I &·- :::> 0 - l 
·); ,. 
. .:.~o 0 
?S .. 'J 
:2 S.tJ 
29 . 1 
2/. 2 
'2 7 . 6 
') 7 . .., 
..:. . '~ 
22.6 
25. 6 
26.0 
:2 ) .4 
27.7 
27 . 08 
..1. r o · c. 
. 1 • .) 4 
29. 9 
29. 2 
?-, ~ 
..... : 0 .... _
25 . 6 
2-t!' ~ 6 
25, 3 
29J. 
23. 4 
27.9 
26.2 
3L O 
27,0 
26.0 
26.8 
26.9 
27.46 
-t-1.803 
8 Standard Deviation 
?Q Q ~- -...J 8 u 
26.lf 
'> "! ? L-- 1 ,.. _ 
26.G 
25., ~: 
'27 .1. 
27 0 7 
29\>8 
28"8 
2 f; 0 6 
2 ~, 0 2 
26,7 
26.8 
28.0 
26.9 
27.3 
+Ll07 
28.9 
26.6 
L.7. 2 
27.2 
?{ ? ~ - !;).,; -
26.4 
26.6 
26 . 9 
27.2 
26o7 
25 c>=) 
~i· oO 
29. 0 
28.3 
27.3 
27.15 
+ ~"t: o~LO 
26.3 
25.3 
25 . 2 
~!~.4 
2S.l 
26 . 6 
27 .0 
27.8 
28 .0 
28.9 
~~ ,. L c..,. o '.i 
27.9 
~6.8 
28.8 
28.(; 
26.98 
+L 465 
25o8 
27.2 
28. 1 
27.9 
29.7 
29.3 
28.3 
28 . 7 
28.4 
26. 7 
26, 7 
:~7 . 0 
28.3 
27.2 
25. 1 
27.69 
+1.302 
Polyenic 
Rl48 D- 5 
27 . 6 
29.2 
25 .8 
26.8 
29.0 
26 . 8 
28 . 2 
26.6 
27 .8 
28.0 
27 . 6 
28.7 
27.3 
25.6 
27.50 
+1.101 
Polyenic 
D- 5 M56 
28.0 
27 . 2 
26 . 8 
28.7 
26. 2 
2g . 4 
26.9 
25.9 
27.3 
27.7 
27.8 
26.9 
26.8 
28.6 
27 .o 
27.41 
+ .958 
Po l yenic 
M900 
27.8 
25.0 
27 .o 
25 .9 
25 .6 
26.5 
25.2 
25.4 
24 .8 
27.2 
25.3 
26.0 
26.4 
27.1 
24.9 
26.01 
+ .949 
i l 
Control 2 
28. 3 
28.8 
27.2 
28.2 
27 . 3 
28.9 
27.6 
28 . 7 
27.6 
28 .2 
27.2 
27 . 9 
24 . 6 
24.6 
27.51 
+1. 357 
"' ~
0 Hour 
4 Hour 
12 Hour 
I II I I 
'I..~BLE 23 
Mean Zones of Inhibition and P Values of ? otassium Penicillin G 5000 U/ml 
in the Bal anced Electrolyte Fluids Tested 
Zone (mm) 
P Va lue 
Zone (mm) 
P Value 
Zone (mm) 
P Value 
at 0, 4 , and 12 Hours Afte r Admixture 
Polysal Polysal 
D-5 
27.26 26o25 
.7)P)o5 • OS)P). 02 
26.79 26.80 
• 7)P).5 P).9 
27.46 27 .31 
• 7) P) .5 , 7)P) . 5 
Polysal Polysal 
D-5 M D- 10 M 
27 018 27.23 
. 9)P) . 7 P).9 
26 .43 23.60 
.S) P).3 • OOl)P 
27 . 15 26.98 
o 9)P). 7 .9)P).7 
Polyenic 
Rl48 
27.58 
.3) P) .2 
25.42 
.S}P) . 3 
27 . 69 
o9)P} .7 
Polyenic 
Rl 48 D- 5 
27.69 
. 9>P).7 
25.97 
.S)P) . 3 
27.50 
• 7)P).5 
Polyenic 
D-5 M56 
27o01 
.9)P).7 
26.43 
.os>P>. 02 
27.41 
.7>P). 5 
Polyenic 
M900 
26 . 32 
• 3)P) o 2 
25.97 
.S) P).3 
26 . 01 
• ool)P 
"' \ ./ 1 
Cont;:-o l 1 
27.6 
26.5 
26 . 8 
?~ -
-i-1 
27 . 6 
28.0 
27.4 
26 <3 
27 (> 3 
27.6 
27.4 
27.8 
28.0 
25. 6 
26.6 
27.21 
a 
+ .698 
a 
I II 
TABLE 24 
Zones of Inhibition of StaphvlQcoccus aureus by Sodium A~picillin SO~g/ml 
in the Balanced Electrolyte Fluids Tested 0 Hours After Admixture 
Polysa l Po lysal Polysa l 
D-5 D- 5 M 
26 . 9 27.8 26.9 
27.3 26.7 27.4 
27.3 27 bt.., 27.3 
27.3 27.:!. 23.0 
27 . 1 27 ~2 24.9 
26.5 27.0 27.2 
27 . 1 27 . 4 28. 0 
27.8 27.5 27.7 
27.7 26.9 28. 1 
27 . 1 27.0 27.9 
27.7 27.3 26 .5 
27.6 28.1 28.2 
27 . 1 27.4 ?- "7 ._fol 
26.0 27 0 0 27.8 
27.8 27.4 26.0 
27 . 25 27.29 26 .97 
+ . 519 + . 356 ±1.415 
Standard Deviation 
Zones of I nhibition (mm) 
Po1ysa1 
D-lO M 
26 .6 
26.5 
28 .0 
27. 5 
27 .5 
28.2 
28. 1 
29 . 0 
27 .6 
28.7 
27 0 0 
28.5 
28.7 
28 . 3 
27.6 
27. 85 
+ .776 
Polyenic 
Rl48 
27 . 0 
26o5 
27.2 
28.2 
25. 0 
29.6 
30.8 
28.6 
27.9 
27.0 
26 .8 
27 .2 
27.4 
26.f+ 
L.7. 7 
27.55 
+1 . 384 
Polyenic 
Rl48 D-5 
27.4 
26 . 8 
27.5 
27 .4 
27 .o 
27.0 
30.2 
29 . 0 
27.2 
27.6 
27.8 
27.8 
29.4 
26 . 9 
27.2 
27.75 
+ .999 
Polyenic 
D-5 M56 
27.8 
28. 4 
28.2 
27.6 
27.2 
27 . 2 
27.6 
27. 7 
28.2 
27 .1 
28 . 4 
26.8 
26.2 
27. 3 
27.3 
27.53 
+ .639 
Polyenic 
M900 
30.2 
27.2 
28.2 
29.0 
28.0 
28 . 2 
30.8 
31.4 
29.5 
29.0 
29.0 
28.1 
30.0 
28.4 
28 .8 
29 . 05 
±1.146 
Control 2 
26.8 
25 .8 
26.0 
26.2 
26 . 3 
27.2 
28 .3 
27.3 
27.5 
27. 4 
28.0 
26. 4 
27.6 
27 .s 
27 . 7 
27.09 
+ .783 
0'\ 
0'\ 
·:::~;:1trol , 
24.7 
26.2 
25 . 4 
25,7 
25.2 
26.8 
25.8 
22.2 
22.7 
26.4 
24.6 
25 . 3 
16.3 
24o5 
24.6 
25.09 a 
+1. 293 
Poly sal 
23.9 
27.0 
26 . 5 
27.4 
26.0 
27. 8 
24.8 
24.3 
25 . 0 
24.1 
25.2 
25 . 0 
24 . 9 
24.3 
24.4 
29.37 
+1. 260 
Tl1.BLE 25 
Zones of Inhibition of Staphylococcus aureus by Sodium Ampici l lin 50JA-g/ml 
in t~e Balanced !:.':l<=ctr clyte Fluids Tested 4 Hours After Admixt ure 
Poly sal 
D- 5 
25.7 
26.4 
26 . 3 
26.5 
2L: .• 4 
27 .6 
25 . 0 
23.7 
24.6 
25 . 2 
25.3 
-> ~ I 
..::.:; ~ ·+ 
24 .9 
23.8 
--
25.28 
+1.078 
Po!.ysal 
D-5 H 
26.4 
26.5 
26.9 
27.8 
23.4 
24.4 
23.8 
24.6 
25.1 
23.8 
25 .4 
25.0 
26.1 
23.9 
25.2 
25.23 
+1. 304 
Zones of Inhibition (r.m) 
Poly sal 
D- 10 t-1 
25.6 
24.4 
25.4 
26.8 
25.3 
24.7 
24.8 
24.2 
24.4 
25.3 
2L;. 2 
25 0::.. 
23.8 
23.6 
25.8 
24.89 
+ .843 
Polyonic 
Rl/+8 
26.4 
25 .l 
23.9 
23.4 
25.6 
23~4 
25.2 
25.2 
23.6 
2.5.2 
24 , 1 
2.:';..8 
25o0 
25.2 
25\)1 
24.75 
+ . 873 
Polyoni c 
Rl48 D-5 
25 . 0 
25 . 2 
24.6 
22. 5 
24.2 
24.9 
24 . 0 
23.4 
24.3 
23.6 
23.0 
23.7 
24.5 
24. 1 
24.2 
24.08 
+ • 747 
Polyonic 
D- 5 M56 
24.8 
25.5 
23.7 
24.8 
24.4 
23.6 
24.4 
23.0 
25 . 4 
23.4 
25.4 
25.3 
25.1 
24.3 
26.5 
24.64 · 
+ .944 
Polyenic 
M900 
25.6 
25.2 
26.2 
25. 7 
25.9 
25.6 
26 . 0 
25.7 
26.t~ 
26.3 
26.0 
25.4 
25.9 
25.7 
26.1 
25 . 87 
+ .334 
aSt andard Deviation 
Control 2 
24.6 
25.0 
23.5 
23.9 
24 . 3 
24.2 
24.4 
23.8 
25.0 
25.1 
24 . 6 
25 . 8 
24 . 5 
26.6 
23.4 
24.58 
+ .849 
0' 
-...; 
TABLE 26 
Zones of Inhibition of Staphylococcus aureus by Sodium Ampicillin • 50~/ml 
Control 1 
25.2 
27.2 
26.8 
24.9 
25 .9 
26 . 7 
27.2 
'25o 7 
25 . 'f 
23.7 
24~6 
26<0 
27.8 
26.0 
26.2 
25 . 95 
+l.096a 
a 
Poly sal 
25 . 8 
28.2 
26 .2 
25.8 
25.8 
27 0 0 
27.8 
25.8 
27o0 
26.3 
26.5 
25.8 
26 . 0 
26.8 
27o0 
26.52 
+ • 767 
Standard Deviation 
in the Balanced Electrolyte Fluids Tested 12 Hours After Admixture 
Poly sal 
D- 5 
24.4 
26.0 
2.5.4 
25.2 
26o3 
26.2 
25.5 
23.5 
24.5 
24.9 
26.6 
24.5 
25o9 
27o0 
25 .5 
25.43 
+ .948 
Polysal 
D-5 M 
23.2 
26.2 
25.7 
26o2 
25.3 
25o2 
26o8 
24.3 
24o 6 
24o 0 
26 . 5_ 
24.6 
24u2 
26.2 
26 . 0 
25.27 
+1.071 
Zones of Inhibition (mm) 
Poly sal 
D- 10 H 
25.0 
25.4 
25 . 8 
25.2 
24.9 
24.5 
24.7 
25 . 5 
24.5 
24.4 
26.0 
24 ,8 
26 o2 
27.0 
25o6 
25.30 
+ . 734 
Polyenic 
Rl48 
25 . 4 
25 .1 
25.3 
25.4 
25.6 
26.9 
26.0 
24.4 
25.4 
25o3 
26 . 0 
25 0 2 
26.9 
26o1 
28.2 
25.81 
+ . 933 
Polyenic 
Rl48 D-5 
24.9 
24.1 
25 . 5 
24 . 1 
24.7 
25.6 
25.9 
25 . 6 
25.9 
25. 1 
26.5 
25.4 
24.6 
25 o8 
25.4 
25.27 
+ .685 
Polyenic 
D-5 M56 
24.6 
24.0 
24.6 
23.9 
23.9 
25.9 
25.0 
25.9 
25.6 
26.4 
26o5 
22 ol~ 
26.0 
26.3 
25 0 6 
25.11 
±1.182 
Polyenic 
M900 
27.ft 
26 .2 
26.6 
26 . 8 
26o7 
25.8 
25.6 
26o0 
26.0 
26.6 
25.8 
25.6 
26.1 
27 . 6 
25o8 
26.26 
+ .628 
Control 2 
27.1 
·· 25.9 
23 0 '~ 
25.2 
25.5 
26 . 4 
24.7 
25o l 
26.0 
25.9 
25o4 
25.2 
25.6 
25.9 
26.4 
25.58 
l- 0 855 
V\ 
co 
Zone (mm) 
0 Hour 
P Value 
Zone (mm) 
4 Ecur 
P Value 
Zone (m.11) 
12 Hour 
P Value 
TABLE 27 
Mean Zones of Inhibition and P Values of Sodium Ampicillin SO~_g/ml 
in the Balanced Electrolyte Fluids Tested 
Poly sal 
27o25 
. 9/P). 7 
25.37 
0 7)P)o5 
26.52 
.2)P).l 
at 0, 4, and 12 Hours After Admixture 
Poly sal 
D-5 
27.29 
. 
• 9)F). 7 
25o28 
o 7)P).5 
25.43 
• 2>P). 1 
P0lysal Polysal 
D-5 M D-10 M 
26.97 27.85 
Polyenic 
Rl48 
·27o95 
• 7)P).5 .05)P).02 .3)P)o2 
25 o23 24.89 24.75 
• 9)P). 7 • 7)p''? . 5 • 7)P)o5 
25.27 25.30 25.81 
.1)P).05 .l)P).os • 9)P). 7 
Polyonic 
Rl48 D-5 
27.75 
.l)P>oo5 
24.08 
.l)P)oos 
2.5 0 27 
.3}P).2 
Polyonic 
D-5 M56 
27.86 
. 2)P).l 
24.64 
o9)P).7 
25.ll 
• 7) P).5 
Polyo~ic 
M900 
29.05 
0 001) p 
25. 8L, 
0 001) p 
26.26 
.ooi)P 
o-. 
1..0 
I II 
TABLE 28 
Zones of Inhibition of St aphylococcus aureus by Te t racyc l ine Hydr och l oride 100~/ml 
in t he Balanced El ectrolyte Fluids Tes t ed 0 Hours After Admi xture 
Control l 
19.3 
18.0 
18.1 
18.0 
19.5 
19.7 
19.2 
19.4 
19.6 
19 . 4 
19.2 
19.6 
l9o 1 
19.7 
19.4 
19 015 
e 
+ . 603 
Polysal 
19 01 
18.4 
18.6 
18.2 
2C.O 
19.5 
19o2 
19.5 
19.5 
19 .l:. 
19o9 
20.4 
18.6 
20.4 
20.3 
19. 40 
+ 0 722 
aStandard Deviation 
Polysal 
D-5 
19.6 
18o3 
19.1 
18.1 
20 . 3 
19 . 4 
19.4 
19.3 
20o2 
19.3 
19.0 
20. 0 
18.7 
20.9 
20.4 
19o47 
+ .788 
Polysal 
D-5 M 
19.4 
18.2 
18.8 
18.2 
20o 1 
19 . 4 
19. 0 
18.8 
19.5 
19.0 
19.2 
20ol 
18o2 
20o4 
20o0 
19o22 
+ . 720 
Zones of Inhibition (m~) 
Poly sal 
D- 10 M 
19.3 
19o3 
18.8 
18.0 
20.4 
20 .0 
20.0 
19 . 5 
21.5 
19.5 
19.6 
21.3 
19o4 
2o.e 
20.0 
19o76 
+ .990 
Polyenic 
Rl 48 
19o4 
19o9 
19.1 
19.9 
19.4 
19.4 
19. 1 
19.0 
17 . 0 
18o7 
19o4 
18o7 
13o8 
18o9 
l9o2 
19.06 
+ .681 
Polyenic 
R148 D- 5 
19o8 
19o8 
19.4 
20. 1 
18 . 6 
19.6 
19.5 
20.1 
17.7 
19o2 
20. 3 
19.7 
19.1 
19 . 8 
19. 6 
19.49 
+ . 655 
. 
Po lyenic 
D- 5 M56 
19.6 
19.7 
19o8 
20.6 
19.6 
19.0 
19o3 
20.5 
1So5 
19.6 
20o4 
19.2 
19 . 0 
20.6 
19 0 l 
19.63 
+ .650 
Polyenic 
M900 
21.0 
20.9 
21.6 
21.9 
20o8 
20.8 
20ol 
21.3 
21.0 
21.2 
20o0 
20o4 
2LO 
21.5 
20.8 
20.90 
+ .522 
Control 2 
20.0 
19.8 
19.7 
20.2 
19.8 
19 . 6 
19.5 
19.0 
18.9 
18.7 
20.0 
19.0 
19 . 2 
19o4 
19.7 
19. 50 
+.452 
-.....! 
0 
TABLE 29 
Zones of Inhibition of St3ryh"lococcus aureus ~y Tetracycline Hydrochl oride lOO~g/ml 
in the Balanced .f..2.2(..Crolyte Fluids Tested 4 Hours After Admixture 
Zone~ of Inhibition (~~) 
Cor..trol l Poly sal Po1ysal Polysa1 Po1ysal Polyeni c Polyonic Polyonic Polyonic Control 2 
D-5 D-5 M D-10 M Rl 48 Rl48 D-5 D- 5 M56 M900 
18.7 18 . 4 18.7 19. 6 20 . 0 20.9 22 . 0 22 .4 24.0 22 .2 
19 . 2 19.1 19.2 19 .6 19.8 19.6 21.6 21.0 22 . 4 21. 4 
18 . 2 18.5 18.4 18.8 19.5 21.6 21.9 21.6 22.9 23.2 
20 . 1 19. 1 18.9 18.6 18.9 20. 8 22.0 22.4 22.6 21.6 
18.9 18.2 18.6 18.9 19.3 20.6 22.2 2 1.0 23.0 21.3 
18.6 18.5 19.0 18.8 20. 4 18.0 19.3 18.6 19.8 19.4 
18.4 17 0 9 18.6 19.4 19. 5 19 . 0 19 .L~ 18 . 4 20.4 19.3 
18 . 4 18,6 19.7 18.6 ., 0 ~ J. ,.,~o~.,j l8.8 19 .2 18.9 20.4 19.4 
18.7 18.1 19.1 18.9 19 .4 18.2 18.2 18. 8 19.6 19.8 
19 .L;. 19.0 18 . 8 18 . 7 20. 0 18 .2 18 . 8 19.2 20.1 18.5 
20.7 21.2 20.4 21.4 21.0 17 0 8 18.4 19.1 20. 4 18.8 
19.4 20.6 21.0 l9.5 21.8 17.9 18.8 19.4 20.1 18 .2 
21.2 20.3 20.4 21 .4 21.8 18.6 19.0 19 . 0 20.3 18.4 
20.3 20.6 20.6 21.0 22.: i S. 2 18.3 18 . 5 20.7 18.9 
20.0 19.8 20.9 21.8 20 ,S 19 , 9 18.8 19.1 20. 1 18.6 
19 . 35 19.13 19.49 19.67 20.25 :!.9 .21 19.86 19.83 21.05 19 .93 a 
+ .921 +1.096 + .926 +1.140 +1. 053 +1.277 +1.5 64 +1.433 +1.520 +1. 587 
'-.J 
l--0 
a Standard Deviation 
Control i 
~1.4 
J.8.0 
18o2 
18o4 
18.2 
18.4 
18.4 
20o0 
18o6 
19o0 
18.6 
17.0 
19o0 
22o8 
19 .0 
19 . 00 
+ .554a 
TABLE 30 
Zones of Inhibition of Staphylococcus aureus by Tetracycline Hydrochloride lOO~g/ml 
i n t he Balanced Electrolyte F~aids Tesced 12 Hours after Admixtur e 
Riysal 
17.9 
17.7 
17o8 
18.7 
18.2 
17.7 
18.5 
17.4 
18.1 
17.6 
18.3 
15 0 6 
19.0 
22 . 6 
18.2 
18.22 
:!:: . • 552 
Po~~ysal 
D-5 
18o5 
18.8 
19. 6 
18.9 
19 . 0 
18o5 
19.5 
l8o5 
19 . 3 
18.8 
17 0 8 
19. 6 
22.8 
19o2 
19.20 
+1.199 
Poly sal 
D-5 M 
19 . 2 
18.6 
19o9 
20 . 1. 
19 .2 
17 . 9 
18.6 
16.6 
18 . 9 
18.2 
16. 6 
19. 8 
22.9 
18.9 
18.2 
18.91 
+1.647 
Zones of Inhib ition (mm) 
Po1ysal 
D-10 M 
19.5 
19.0 
19 o1 
18 . 8 
20 . 2 
18.2 
19.4 
18.0 
19o6 
19. 0 
16oe 
20.3 
23.7 
19.3 
--
19.35 
+1. 600 
Polyenic 
Rl48 
18. 8 
l7 o7 
18. 0 
18.6 
18.0 
17 .8 
l8o0 
.17 . 0 
l7 o8 
18 .0 
l8.L~ 
17.8 
17 . 5 
17.9 
--
17 0 95 
.452 
Polyonic 
Rl48 D-5 
17o9 
17.5 
18.0 
17.9 
18 .6 
18 . 4 
18.8 
19o0 
18o9 
l8o8 
l9o0 
18. 7 
18.6 
17 0 6 
18.9 
18.44 
+ .544 
Folyonic 
D- 5 M:S6 
18.1 
19o2 
18.7 
19.1 
19.4 
18.5 
19.2 
18.8 
18o8 
18o0 
17.8 
19.4 
l 8o9 
. 18 0 8 
l 8o8 
18. 77 
+ .514 
Polyonic 
M900 
17 o9 
19o7 
20 . 9 
18.9 
20 . 4 
19.8 
20.1 
20.0 
l9o3 
l9o9 
19.9 
19.9 
20ol 
l9o4 
l9 o7 
19.73 
+ • 712 
aStandard Deviation 
Control 2 
20 . 2 
18.2 
18.9 
18.7 
18. 9 
17.7 
18.4 
17o7 
18o 0 
l8o6 
18 o8 
18.9 
18.6 
18.9 
20.0 
18.70 
+ .737 
-....: 
N 
0 Hour 
4 Hour 
12 Hour 
I 
TABLE 31 
Mean Zones of I nhibition and P Values of Tetracycline Hydroch l or ide l OO~g/ml 
in the Ba l anced Electr olyte Fluids Tested 
at 0 , 4, anJ 12 Hours After Admixtur e 
Polysa1 Polysal Pulysa1 Polysa1 Polyoni c 
D-5 D- 5 M D- 10 M Rl48 
Zone (mm) 19o40 19o47 19 . 22 19.76 19o06 
P Value .5)P) o3 o3)P). 2 • 9)P) . 7 o05) P). o2 o05) P) . o2 
Zone (mr:l) 19. 13 19o49 19 . 67 20 o25 19 o21 
P Value o7)P) o5 o7)P).5 . 5} P) . 3 .02) P) o01 .2) P) o1 
Zone (mm) 18. 22 19o20 18o 9l l9o35 17 0 95 
P Va l ue • 3)P) o 2 o 9) P) . 7 o9)P)o7 o 7)P) . 5 o0l) P) . 001 
Po 1yonic 
Rl48 D- 5 
19o49 
P) o9 
19o86 
o 7>P) o5 
18 . 44 
o 3) P) o 2 
Polyoni c 
D- 5 M56 
19o63 
o 7) P) o5 
19. 83 
o 9) P) . 7 
18o 77 
o9)P) o7 
Po1yonic 
M900 
20. 90 
0 001) J' 
21. 05 
o 1) P) . 05 
19o73 
. OOl)P 
-...: 
w 
Ccr-,trol 1 
25.0 
25.9 
26.1 
25.3 
26.5 
25.5 
26.1 
26.0 
26.2 
25.9 
24.0 
24 . 4 
26.0 
23.8 
24.1 
25.39 a 
+ .904 
Poly sal 
26 . 4 
25 . 3 
24.6 
25.7 
26.4 
24.6 
25.7 
25 . 8 
25.2 
25.7 
26o l 
24.9 
25.4 
23.8 
24.5 
25.34 
+ • 747 
TABLE 32 
Zones of Inhibition o£ £taphylococccus aureus by Sodium Cephalothin 1 2 . 5~~g/ml 
iP. the Balanced Electrolyte Fluid3 Tested 0 Hours After Admixture 
Polysa. l 
D-5 
24.8 
24.6 
--
--
25.8 
24.9 
25.5 
23.0 
25.7 
2Lf. 3 
26.0 
25.2 
24.5 
24.1 
25.9 
25o29 
+ .674 
Poly sa l 
D-5 M 
25 .o 
25 . 2 
--
--
23.4 
24 . 6 
25.7 
25.0 
25.4 
25.1 
25.6 
24.3 
26.1 
24.0 
24.6 
24.92 
+ 0 740 
Zones of IP.hibition (mm) 
Po l ysal 
D- l O . .M 
25.2 
25 . 7 
2!.1 .• 9 
24.7 
24.1 
24.9 
25.9 
26.1 
26.0 
25.0 
24.4 
24 . 3 
25.2 
25.9 
25.0 
25.13 
+ .642 
?olyonic 
Rl48 
25.9 
23 . 7 
29.0 
24.0 
23.0 
23.1 
23.7 
24.4 
25.2 
--
24 . 6 
25.6 
25.0 
24.7 
26.8 
24.59 
+1.043 
Polyeni c 
Rl48 D- 5 
24.0 
2L;. 0 
24~6 
23.9 
25.3 
24.2 
23.8 
24.0 
2Lf. 5 
25.1 
24.4 
23.9 
24.9 
24.0 
24.7 
24 . 35 . 
+ .524 
Po l yenic 
D-5 M56 
23 . 8 
23.9 
2!.f.8 
24.5 
24.6 
23.4 
23 . 7 
2L~ . 2 
24.3 
24 . 0 
25.7 
25.5 
24.7 
23o9 
2Lf o 7 
24o38 
+ .655 
Polyenic 
w~oo 
24.7 
25.5 
25.4 
25.4 
26.8 
24.6 
23.9 
25.2 
22.2 
23.2 
25o9 
~5.4 
24.6 
23.3 
26.1 
24. 95 
+1.158 
eStandard Devi ation 
Control 2 
26.1 
24 . 9 
25.5 
25.4 
26.1 
23.0 
24 .3 
24o l 
23.6 
25.7 
24.8 
25 . 4 
24.8 
25 . 9 
26.4 
25.07 
+ .981 
...... 
J:.. 
Control 1 
26.9 
23.8 
25 . 1 
23.4 
24.8 
25.8 
25 . 9 
26. 0 
26 .1 
25 . 5 
25.0 
26.4 
26.6 
25.7 
26 . 6 
25 . 5 
a 
+1. 007 
TABLE 33 
Zones of I nhibit i on of Staphylococcus aureus by Sodium Cephalothin :2 . 5/Ag/ml 
in the Balanced Electrolyte Fluids Tested 4 Hour s After A~dmixture 
Polysal Polysal Polysal 
D-5 D-5 M 
24.5 25.8 27.8 
23.6 23.1 23 . 3 
25.4 25.4 25 . 0 
25.3 23,, 9 24.0 
26.6 26.7 26 .3 
26.1 24.2 25.9 
25.6 27.4 25.2 
25.1 25.8 26.2 
25.7 25.9 26.2 
26.5 25.9 25.9 
25.6 26.7 25.0 
26.8 25.1 26.8 
26.2 25.2 25.3 
25 .7 26.3 25.8 
26 .9 25.9 25.6 
25.71 25 . 53 25.62 
+ .886 +1.131 +1. 0&6 
Zones cf Inhibition (mm) 
Polysal 
DlO H 
25.8 
22.8 
26.8 
23 .4 
25.5 
26.5 
26.2 
25 . 3 
26.2 
24.1 
--
--
26.4 
25.0 
26. 1 
25.39 
+1. 249 
Polyenic 
Rl48 
23.8 
23.7 
25.3 
24.5 
24.3 
25.8 
24.6 
25.2 
25.4 
26.1 
2 5.4 
2.).6 
24.4 
24.9 
24.6 
24.91 
+ 0 712 
Polyenic 
Rl48 D-5 
25.4 
25.0 
24.7 
25 . 1 
25.4 
26.1 
24. 4 
25.2 
25.0 
25.6 
26.0 
24.1 
24. 9 
25.2 
25.6 
25 . 18 
+ .543 
Polyenic 
D- 5 M56 
25 . 1 
26.8 
25.8 
25.1 
25.2 
24.5 
23. 9 
25.1 
25.8 
25.2 
24.7 
25.4 
24.7 
24 .3 
26.0 
25.77 
+ .730 
Polyenic 
!1900 
25.2 
24.6 
25.7 
24.4 
24.2 
24.1 
24. 3 
25.0 
24 .4 
25.7 
24.6 
25 . 7 
25 .o 
25.4 
24.4 
24.91 
+ .559 
aStandard Deviation 
Control 2 
25 .8 
25.0 
25 .5 
24.9 
25.0 
25 .0 
2L.. .6 
25.8 
25.2 
25.5 
25 o2 
2 I , . 
'+oO 
21+.6 
/:4 ~· 8 
2l;~ .6 
25.07 
+ .420 
" V1 
Control l Poly sal 
26.5 26,9 
26,3 26,9 
25.4 25.9 
26,2 26.1 
25.5 25.4 
23.8 23.9 
25.4 24.3 
23o0 24.6 
25.4 25.5 
24o3 25.2 
25.3 25.2 
25 o6 25.8 
25.3 25.7 
25.1 26.2 
25.2 25.1 
z- ?2 ::;,..... a 25o51 
+ .922 ± .854 
'" •---••>-•-· __ ,,.._." - -· ,._ ... -··· '•"-'"'" -~-···· ·-···----~-----l----- ---
TABLE 34 
Zones of Inhibition of Staphylococcus aureus by Sodium Cephalothin 12.5/)-g/ml 
in the Balanced Electrolyte Fluids Tested 12 Hours After Adrr.ixture 
lilly sal 
D-5 
26.0 
27.0 
26.4 
26.0 
26.1 
24.6 
25.7 
24.4 
25.4 
24.6 
24.6 
25o~ 
24.4 
24.9 
26.7 
25.46 
±.869 
Polysal 
D-5 M 
25,8 
26.5 
25.7 
26.4 
26.4 
24-. 1 
26.4 
24.6 
25.0 
24.2 
25.4 
26.3 
24.1 
24.5 
26.0 
25.43 
± .928 
Zones of Inhibition (mm) 
Poly sal 
D-10 M 
26.3 
25.2 
25.8 
26.7 
26.4 
22,6 
25.0 
24.1 
23.9 
23o8 
23,4 
23.8 
24.6 
24.4 
--
24.62 
::!::1. 277 
Polyenic 
Rl48 
24.9 
24,2 
25.0 
24.9 
24.6 
24.4 
25.3 
24ol 
2!1,.3 
25.7 
25.0 
23o9 
24,8 
24.0 
25.6 
24,85 
± .682 
Polyenic 
Rl48 D-5 
24.1 
25.0 
25.7 
25.0 
23,9 
23.7 
24.4 
24,6 
25.8 
25.1 
25.0 
25.0 
23.9 
24o5 
24.2 
24.66 
± .640 
Polyenic 
D-5 M56 
24.2 
24.4 
24.8 
24o3 
25.1 
24o3 
24.6 
25o0 
24.4 
24.7 
25.3 
24o6 
26.1 
25.4 
24,6 
24.78 
± .412 
P"lyonic 
M900 
24.2 
25.9 
25.5 
24.9 
24.9 
24.9 
25.4 
25,0 
25.2 
24.1 
24,8 
23.9 
24,2 
23,2 
23.4 
24.50 
::!.: • 711 
Control 2 
25.0 
25.2 
26.4 
25.3 
29.9 
26o0 
25.6 
26.0 
25 .o 
25o0 
25.9 
23.8 
24.2 
23.8 
25.2 
25.19 
±· 780 
,, 
"' a Standard Deviation 
Zone (mm) 
0 }\our 
P Value 
Zone (mm) 
4 Hour 
P Value 
Zone (mm) 
12 Hour 
P Value 
TABLE 35 
Mean Zones of Iriliibition and P Value of Sodium Cephalothin l2.5/~g/m1 
in the Balanced Electrolyte Fluids Tested 
at 0, 4, and 12 Hours After Admixture 
Po1ysa1 Polysal 
D-5 
26.34 25o 29 
• 9)P). 7 o i)P) .5 
25o71 25o53 
• 9)P). 7 P}.9 
25o5l 25.46 
o5)P)o3 .5)P).3 
Poly sal 
D-5 M 
24o92 
• 2)P)o 1 
25.62 
P).9 
25.43 
o5)P).3 
Polysal 
D-10 M 
25o 13 
,5}P)o3 
25o39 
• 7)P)o5 
24o62 
o3)P)o2 
Polyenic 
Rl48 
24o59 
o3)P)o2 
24o9l 
o5)P)o3 
24o85 
• 3)P) o 2 
Polyenic 
Rl48 D-5 
24o35 
.05)P}.02 
25o18 
• 7)P)o5 
24o66 
o l)P)o 05 
.... , ............ --... --1-.. -·-···-
Polyenic 
D-5 M56 
24.38 
o05)P}o02 
25o77 
• 7)P)o5 
24o52 
o l)P).05 
Polyenic 
M900 
24.95 
o9)P)o 7 
24o 91 
o5)P).3 
24o50 
o 02)P) o 01 
'-' 
._, 
' .... , ______ _,.1.,_,,, ... --. ---
:ontrol 1 
19 0 0 
2L3 
20.4 
21.0 
20.3 
21.4 
20o7 
20.,8 
20o9 
19o4 
18o6 
20o8 
18o3 
20.8 
18o3 
20o 13 
:!:1. lOOa 
.... """ .. "'' -·-~ _,,..,, ..... ,-.... ·~· -~ ~·" . "'" '' 
TABLE 36 
Zones of Inhibition of Staphylococcus aureus by Carbencillin Disodium loOmg/ml 
in the Balanced Electrolyte Fluids Tested 0 Hours After Admixture 
Polysal 
21.0 
20o8 
20o4 
19o9 
20o3 
21.8 
20o8 
2lo 7 
22.0 
20.2 
20.2 
18o7 
19o2 
21.3 
l7 o8 
20,41 
+lo169 
Polysal 
D-5 
22oO 
20o3 
21.0 
22o0 
19o2 
20.4 
20o8 
21.1 
19,3 
l8o9 
21.0 
18o3 
21.8 
21.3 
19.5 
20o44 
±1o2l6 
Poly sal 
D-5 M 
22o6 
20o2 
20o8 
21.5 
22o2 
20o3 
22o0 
20o 7 
20ol 
21.0 
20o0 
19o6 
20.0 
21.2 
20o2 
20o83 
± o907 
Zones of Inhibition (mm) 
Poly sal 
D-10 M 
21.2 
20ol 
20.5 
21.4 
20o9 
20.3 
2lo 6 
21.5 
20.9 
21o9 
22o1 
19o5 
19~8 
18o2 
l9o4 
20o68 
±1.056 
Polyenic 
Rl48 
20o2 
19o2 
l8o9 
21.2 
19o9 
19o3 
19.5 
19o9 
20o4 
20.3 
19.7 
20ol 
2lo3 
2lo1 
20o8 
20o12 
± '745 
Polyenic 
Rl48 D-5 
19o5 
20o6 
20o4 
19.5 
20.3 
20o6 
20o0 
20o0 
20o4 
20o4 
20o8 
18o2 
20o0 
22.1 
19.5 
20ol5 
± .844 
Polyonic 
D-5 M56 
l9o6 
19o7 
19o9 
19.4 
20,6 
19o6 
19.3 
21.1 
19.8 
21.9 
20o0 
19 0 9 
19o4 
20.4 
20o5 
20o07 
± o717 
Polyenic 
M900 
20o6 
20o4 
21.6 
20o4 
21.1 
19.9 
2lo6 
19o8 
20o2 
21.8 
20o2 
20o8 
20.7 
20o3 
20o6 
20o67 
+ o615 
aStandard Deviation 
Control 2 
20o6 
20o0 
20.0 
20o1 
20o2 
20o0 
20o1 
20.5 
21.4 
20o5 
20o0 
l9o8 
20o4 
20o4 
20o8 
20o32 
+ o409 
..., 
"" 
·----·-·-···--·-··--.J.. ----- ---
Control 1 
19.8 
19.2 
18.0 
19 0 6 
20.2 
20.1 
19.6 
21.3 
20.2 
20c6 
ZOoS 
20.4 
19.3 
18.6 
20.8 
20.15 
±lo088a 
a 
TABLE 37 
Zor.es of Inhibition of Staphylococcus aureus by Carbenicillin Disodium l.Omg/ml 
in the Balanced Electrolyte Fluids Tested 4 Hours After Admixture 
Polysal 
21.6 
19.4 
19.6 
18.5 
20.0 
20.0 
2LO 
22.2 
20.9 
21.0 
20.6 
19.0 
18.6 
19.4 
20.5 
20.10 
+ .628 
Polysa1 
D-5 
20.8 
20.4 
19.7 
20.6 
20.1 
20.8 
19o2 
20.5 
19.6 
19.5 
20.3 
19.3 
19.2 
20.5 
2lo0 
20.27 
±1.173 
Poly sal 
D-5 M 
2L3 
20.0 
--
19.8 
20.8 
2L6 
20.0 
22.7 
21.3 
19o4 
20.3 
19.4 
18.2 
20.1 
19.0 
20.34 
±1.211 
Zones of Inhibition (mm) 
Polysal 
D-10 M 
2lo6 
19.4 
19.0 
20.6 
2lo0 
21.0 
--
2lo6 
20., 1 
20.8 
20.8 
2lo6 
18.3 
18.3 
20.6 
20,42 
j:lol52 
Polyenic 
Rl48 
19.5 
20.2 
19.3 
19.6 
20.6 
20.7 
21.6 
19.0 
19.7 
20o6 
19.9 
21.3 
20o7 
19o4 
20.0 
20.14 
.:!:: • 759 
Polyenic 
Rl48 D-5 
2lo0 
19.1 
19.5 
18.7 
18.5 
20.7 
19.5 
21.2 
20.0 
19.8 
21.0 
2lo8 
--
22.3 
19.8 
20.21 
+l. 150 
Polyonic 
D-5 M56 
19.4 
19.1 
19.6 
19.6 
20.9 
2L2 
19.8 
20.1 
20.2 
2L4 
20.6 
20.6 
20.9 
20.0 
18.8 
20.15 
.:!:: • 776 
Polyonic 
M900 
18.8 
18.8 
19.8 
19.4 
19.6 
19.4 
19.8 
--
19.7 
18o9 
19.0 
19.3 
19.3 
19.0 
19.3 
19.29 
.:!:: .467 
St~nclard Deviation 
Control 2 
21.0 
2lo2 
20.6 
20.8 
21.0 
20.4 
19.8 
21.6 
18.7 
17 .o 
21.3 
19.3 
l8o4 
22.5 
20.7 
20.29 
.:!::1.418 
.._, 
'"' 
Control 1 
20.4 
18.4 
1 0 • ~0. J. 
19g4 
13.4 
19g0 
19.5 
18.8 
18.3 
18.6 
18.7 
l9o9 
l7. 8 
17.7 
17.8 
18.73 a 
+ • 797 
a 
··-···· ·-~-~~---·--··__J_··----- -----····-·-··-
'"'"" ... ~ ,,.,_ ..•. ··-····~-·---~·· ~~ .. -·--·· ........ '' 
TABLE 38 
Zones of Inhibition of StaPhylococcus aureus by Carbenicillin Disodium l. Omg/ml 
in the Balanced Electrolyte Fluids Tested 12 Hours After Admixture 
Zones of Inhibition (mm) 
Polysal Polysa1 Po1ysa1 Polysal Polyenic Polyenic Polyenic Polyenic 
D-5 D-5 M D-lO·M R148 Rl48 D-5 D-5 M56 M900 
21.0 20.6 21.1 19.6 19.5 18.5 19.4 16.1 
18.9 20.5 19o7 18.7 18,7 19.6 18.8 16,4 
19.5 19.8 19,3 19.8 20,4 20.7 20o3 16.0 
19.4 19.3 18.2 18.7 l::J.4 18o9 17.6 17 g4 
19,7 20.3 20.3 19.8 l8o3 18.5 17.8 17 0 3 
19.4 l9o0 19.2 18.3 20.9 19 .. 8 20.2 20.0 
19.8 19 0 6 19 .. 9 19.0 18.,7 20.6 19.8 18o4 
18,2 19.2 18.7 19.3 19o8 18.6 19.8 18.0 
20.3 18.6 l8o2 13.1 l7 0 9 19.,6 19 0 1 18. 1 
19,1 18 .. 7 18.8 17 .,/.:. 19o8 19.3 18o3 17 .,5 
18.9 18.9 17.9 19.8 1 o A .... ':JoV 18.3 19.1 17.5 
17 .. 5 18 .. 7 19.2 18.,6 19. 1 17 0 8 17.6 17.6 
17.7 19 .. 2 17.2 l9o7 19 .. 0 19 0 6 18.4 16.3 
17.2 18.0 19.2 17.1, 20,.1 19.3 19o6 17 0 6 
17:.3 17 .. 6 18.9 17 .. 6 20.1 18.9 20.6 16.8 
18.93 19.20 19.05 18.78 19.31 19.25 19.09 17.40 
±1o 135 + .861 ± .980 +. 797 ± .858 + o824 ± .987 :!::1.033 
Control 2 
18.0 
18.7 
18.3 
19.8 
18.9 
21.2 
20.0 
19o5 
18.9 
18 .. 7 
19.4 
18,4 
18.3 
19.0 
18.0 
19.04 
+ .843 
co 
0 
Standard Devia. ti on 
0 Hour 
4 Hour 
12 Hour 
-..... ____________ ..l, ...... _, ___ _ 
TABLE 39 
Mean Zones of Inhibition and P Values of Carbenicillin Disodium l,Omg/ml 
in the Balanced Electrolyte Fluids Tested 
Zone (mm) 
P Value 
Zone (mm) 
P Value 
Zone (mm) 
P Value 
at 0, 4, and 12 Hours After Admixture 
Polysal Polysal 
D-5 
20.41 20.43 
• 7)P).5 .5)P).3 
20.15 20.10 
.5)P).3 .5)P).3 
18.93 19.20 
• 7)P).5 • 2)P).l 
Polysal Polysal 
D-5 M D-10 M 
20.83 20.68 
.l)P).05 .3)P).2 
20.27 20.42 
.S)P).3 .3)P).2 
19.05 18.78 
.S;>P).3 .9)P).7 
Polyonic 
Rl48 
20.12 
.5)P).3 
ZOo 14 
.9) P).7 
19.31 
.5)P}.3 
Polyenic 
Rl48 D-5 
20.15 
.S)P).3 
20.21 
.9)P).7 
19.25 
• 7)P).5 
Polyonic 
D-5 M56 
20.07 
.2}P) .1 
20.15 
• 9)P). 7 
19.09 
• 9)P). 7 
Polyonic 
M900 
20.67 
.l)P).os 
19.29 
.02)P).Ol 
17.40 
.OOi)P 
00 
,_. 
Contra 1 1 
25o2 
25o8 
25o0 
27o4 
26o5 
25o7 
26 .. 2 
26.,3 
J7oJ. 
25o4 
26,2 
26,,2 
27,7 
26o9 
2 5o6 
26o2l 
·± 0 799 
a 
a 
Polysal 
26o2 
26.6 
27 01 
26o7 
27o0 
26o2 
26o5 
26o5 
27o3 
28o1 
26o2 
26o6 
26o2 
26o1 
26,9 
-
26,68 
TABLE 40 
Zones of Inhibition of Staphvlococcus aureus by Sodium Cefazolin l.Omg/ml 
in the Balanced Electrolyte Fluids Tested 0 Hours After Admixture 
Zones of Inhibition (mm) 
Poly sal Po1ys<:l I'o lysal Polyonic PoJ.yonic Polyonic 
D-5 D-5 M D-10 M Rl48 Rl48 D-5 D-5 M56 
25o5 2So 8 25o4 27o5 26o2 26o0 
25o 6 25,6 26o4 26o0 26o0 27 0 2 
26oC 27o2 26o5 27o4 27 0 3 25o 6 
2co l 26o7 25o7 26o6 27o4 25o6 
25o7 26o3 27 0 7 26o8 26o4 26o7 
25o 2 27 0 1 27o6 26,4 27,4 27,4 
25 .. 6 26 .. 3 26o7 26o5 26o2 26o4 
26o7 L6o2 26o7 2.7 .. o 26o0 26,3 
26~0 27o7 26o3 26.8 26.3 26o2 
26o0 25o9 25 .. 9 26,[:, 27 0 7 27o7 
26o5 26o0 25o4 26,4 27,7 26.7 
25o9 25o4 2i 0 3 26.3 26o1 27 0 0 
26,1 26o5 26.3 26o0 26.1 27o1 
26o2 26 .. 2 26o0 26.4 26o5 26o3 
25o 2 25.4 27' 3 27 o4 26o4 26o2 
26,02 26,29 26o43 26o66 26o65 26o56 
::!: o539 ± ,409 + o667 ::!: o666 :!:: ,482 ::!: o648 +o628 
Standard Deviation 
,,,~,. .. __ .. _, _ _j.,,,, ___ .... 
Polyonic Control 2 
M900 
24o6 27o1 
25o2 26o4 
25o0 26o 0 
24o2 26o4 
24o0 25o0 
24.3 26o3 
24.7 26o7 
24o6 26o6 
25o5 26o6 
24.9 26o0 
25,0 26o4 
25o1 26o2 
24o7 27 o2 
25 o6 27o3 
25o4 27 0 7 
24o86 26o46 
+ o485 + o625 
co 
N 
Control 1 
27 . 6 
28.0 
28.0 
28 .2 
29.3 
28.0 
28 .2 
23 . 4 
27.8 
27.4 
28.2 
28.7 
29 . 0 
28 .7 
28 . 2 
28.25 
+ . 510 a 
a 
Poly sal 
28.2 
27.0 
28.1 
28 . 6 
29.0 
28.1 
28.6 
28.3 
28. 6 
28.4 
28 . 5 
27.7 
28.0 
28 . 3 
29. 0 
28.29 
TABLE 41 
Zones of Inhibition 1Jf: Staphylococ:._cus a•Jreus by Sodium Czfazolin l.Omg/ml 
in the Balanced Electrolyte Fluids Tested 4 Ho:.1rs Af::er Adn~ixture 
Zones of Inhibition (~m) 
Poly sal R:U.ysal Po l y sal Polyoni c Polyonic lblyonic 
D-5 D-5 M D- 10 M R148 R148 D- 5 D- 5 M56 
28.5 28.6 28.5 29.4 28.4 29.2 
~7~2 28 . 6 27.0 28.3 28.5 28.2 
28.4 28.1 28.6 28.3 28.3 28 . 0 
23.4 29 . 7 28.C 27.0 27.6 27.3 
28 . 2 28.7 28.0 28.7 29.6 28.6 
2S3e3 28.7 27.3 28.4 28.4 28.6 
27.7 28.3 27.5 28.4 28.3 28.4 
28.3 27.9 28.7 29.0 29.0 28.5 
?.7 0 6 28 . 3 27.3 28.7 27.3 28.7 
28.8 28.7 28 . 9 27 o7 28. 9 28 . 0 
27.0 29.1 28.1 28 . 6 -- 29.1 
26.4 28.7 27.5 28 .6 -- 28 . 3 
28 . 4 28 . 0 27.6 28 . 5 28.8 28.7 
27. 2 27. 6 27.3 2 8~ 1 28.6 28.9 
ze.s 27.1 23.7 28.3 28.3 28.1 
27.43 2~3.,4. 1 27 0 93 28.40 28.43 28.44 
± .502 + . 699 + .625 ± .625 + .548 ± .569 + . 485 
Standard Deviation 
Po1yonic Cont rol 2 
M900 
26o 7 28 . 5 
25.3 27.2 
26 . 6 29.6 
27.2 27.8 
24.8 28.6 
25.3 28.3 
25.7 27.2 
26.4 28.2 
26.6 29.0 
26.6 29 . 0 
26.3 28 . 7 
25.3 28.3 
25.7 28.2 
26.1 29.0 
26.0 28.3 
26 .04 28.39 
+ .673 ± . 655 
OJ 
w 
......... , __ ,_ .. __ .. _..J., --....... ' 
Ccntrcl 1 
2.6.2 
29.3 
28o0 
28.7 
27.6 
28.7 
28.2 
') ("• {'; 
.... ') e ,J 
28.,7 
26.4 
2773 
Zf,,3 
2S.,2 
28.2 
28.,06 
2:: • 9l0a 
Polysal 
26.,9 
28o6 
28.1 
28.0 
29.2 
28.6 
28.1 
29.,0 
28.2 
27.,0 
27.6 
28.3 
29.,0 
28.3 
28.4 
28.28 
TABLE 42 
Zones of Inhibition of Staphvlococcus aureus by SodiQ~ Cefazolin 1.0mg/ml 
in the Balanced Electrolyte Fluids Te.sted 12 Hours After Admixture 
Zones of Inhibition (mm) 
Polysa1 Po1ysa1 Pc1ysal Po1yonic Polyonic Polyonic 
D-5 D-5 M D-lO M Rl48 R148 D-5 D-5 M56 
28.0 27.9 28.0 26,6 26.7 27.9 
27 0 l 27 0 6 29.6 28,1 ' 28.0 25.3 
28.2 28.0 29o6 27 0 7 28o 1 27 oO 
27.2 28.3 26.7 28.6 27.,7 27,7 
27.7 28,2 28., 1 27 c 9 28 o2 '27,9 
27 .,3 27 0 7 28.1 27 .,3 28.5 26.9 
28.6 27.,6 2 8.3 28,0 27.7 26.5 
27 0 7 27.,6 27.7 28,0 27.6 27.1 
28o7 28.5 27.3 27 .o 27.0 2.7 ,4 
28.3 28.4 27.6 26.,3 27.7 27.7 
28.4 27.7 28.,1 27.9 28.2 26.9 
27,7 28.1 28.3 28.1 27.0 26.8 
-- 28.3 28.,5 27 .. 6 28.3 27.7 
28.5 27.7 28.,2 21.,4 27.2 27.3 
28.,1 28.4 28"0 27.4 27.0 26,3 
27.96 27.,93 28.14 L7 .39 27,66 27.16 
± .583 + .526 :!: • 405 :!: • 192 :!: • 665 + .564 + .551 
a Standard Deviation 
Polyenic Control 2 
!1900 
23.4 27.4 
26o0 27 .o 
26.2 29.2 
24.6 28.1 
28.6 26.3 
26.2 26.5 
2~. 5 27.3 
26.3 27 .,4 
26.5 <").... -, ,e../ o I 
26.5 26<>7 
26.8 26.4 
25.3 27.7 
26.,7 27,1 
25.4 26,4 
26.3 27. 2 
25.93 '27.24 
+L208 + .768 
"" 
·"' 
Zone (mm) 
0 Hour 
P Value 
Zone (mm) 
L~ Hour 
P Value 
Zone (mm) 
12 :'!our 
P Value 
,, , ........ ,. ·"- ···•· , ... _., .... -.. ~ ..•. ~.·~· . ~-·'-" ...... 
TABLE 43 
Mean Zones of Inhibition and P Values of Sodium Cefazolin loOmg/ml 
in the Balar,ced Electrolyte Fluids Tested 
at 0, 4) az1d 12 Hours Aft2r Admixt:..J.re 
Polysal Polysal 
D-5 
26o68 26.02 
o l)P}o05 o5}P:>o3 
28o29 27o93 
o 9) P). 7 , 2)P). 1 
28o28 27.96 
o5>P).3 0 7:>P)o5 
Polysal Polysal 
D-5 M D-10 M 
26o29 26o43 
o 9)P)o 7 o5)P).3 
28o41 27o93 
.S)P)o3 o 2)P)o 1 
27¢9J 28oJ.4 
.7)Pi.5 o9)P).7 
Polyenic 
Rl48 
26o66 
.5)P) o 3 
28o40 
P)o 9 
27 o39 
o2)P)o 1 
Polyenic 
Rl48 D-5 
26.65 
.5)P}o3 
28o43 
o9)P)o7 
27o66 
o l)P)oOS 
·--·-··-··-·...l .... ---- ,..... '' -
Polyenic 
D-5 1"06 
26.56 
.7)P)o5 
28o44 
o9)P)o7 
27.16 
o5)P)o3 
Polyenic 
H900 
24o86 
0 001} p 
26o04 
o OOl)P 
25.43 
oOOl}P 
(.(; 
'-" 
.,.._ '""" ··-"-"""_,_,...... . '"-' -.-.---·-··-~·- ,, ·····---·---···.-J.·-···--·--·-
TABLE 44 
Summary Table of Results of Physical, Spectrophotometric, 
end Microbiological Compatibility Tests 
Drug Polysal Polysal Polysal Polysal Polyonic Polyonic 
D-5 D-5M D-lOM Rl48 Rl48 D-5 
Aminophylline ca c c c c n c. 
Metaraminol Bitaitrate c c c c c c 
Trimethaphan Camsylate c c c c c c 
Hydrocortisone Sodium 
Succinate c c c c c c 
Methylprednisolone Sodiuo 
Succinate c c c c c c 
Potassium Chloride c c G c c c 
Sodium Heparin c c c c c c 
Sodium Bicarbonate c c c c c c 
Soditur. Pen~obarbital X X X X c X 
Vitamin B Comple.x 
Hith C c c c c c c 
Potassit~ Penicilli~ G c c c c c c 
Sodium PJTipicillin c c c c c c 
Sodium Cephalothin c c c c c c 
Tet:'acycline Hydrochloride c c c c X c 
Carbenicillin Disodim1t c c c c c c 
Cefazolin Sodium c c c c r' c v 
Polyenic 
D-5 M56 
c 
c 
c 
c 
c 
c 
c 
c 
X 
c 
c 
c 
c 
c 
c 
c 
2 C= compatible adreixture as determined by physical, spectrophotometric) or microbiological 
assay results 
Polyenic 
M900 
xb 
X 
c 
X 
X 
c 
c 
X 
X 
c 
X 
X 
c 
X 
X 
X 
bX= incompatible admixture as determined by physical, spectrophotometric) or microbiological 
assay results 
00 
c;y, 
Chapter 4 
DISCUSSION 
'The primary objectives of this study were to examine the com-
patibility of selected drugs in a series of balanced e l ectrolyte 
solutions. The?e objectives were established because of the apparent 
l ack of this specific information, with the purpose of making such 
information available to benefit the user of such combinations. Reviewing 
pas t work on IV incompatibilities , reliable procedures for such a 3tudy 
were outlined. The need for determining chemical, or non-visual 
compatibili tic::s ~~as of paramount importa.nce. This was achieved using 
spectrophotometric techniques, designed to det ect &ny changes in the UV 
spectra of certain of the drugs in admixture. Microbio l ogical assay was 
used in det ermining the activity of the antibiotics examined. The three 
techniques (physical, cher,1ical, and microbiological assays) have been 
emp l oyed by other researchers (20 , 40, 44, 46) and ar e generally accepted 
as valid methods. 
The maj.n rarameter used in choosing the drugs for examination wa<:> 
the p:robable inci(lence of usage of the therapeut ic agents . In reviewing 
the literature, it becomes obvious that these agents aTe being used 
l'/ide ly, and therefore, should be examined i n detail. 
Aminophylline in combination with the various fluids showed no 
physic:1l signs of i ncompat:ib:ili ty . Al so , no significant changes .Ln pH 
occurred in any of the admi xtures . l.lowever, chemical ana l ysis showed the 
87 
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UV spectra of aminophylline to be altered in Polyenic M900 at 0, 4, and 
12 hours after admixture. Polyenic M900 has a pH of 4.1, while 
aminophylline is alkaline in nature. One might predict the change in UV 
spectra to be due to this acid-base reaction. However, Parker (SO) 
reports aminophylline to be stable even in pH as low as 3. 5. Perhaps 
another explanation of the change might relate to an interaction between 
the drug and the alcohol in the Polyenic M900 (4 ml/100 ml). An exact 
mechanism is not known. 
Metaraminol bitartrate in admixture with the fluids tested 
presented no physical signs of incompatibility, and pH variation was 
insignificant. However, like aminophylline, metaraminol showed an altered 
UV spectra in the Polyonic M900 solution. Again, this cannot be attrib-
uted solely to a low pH. Parker (51) reports metaraminol to be stable 
in a pH range of 3.6 to 7.6, and Anderson and Latiolais (52) reported 
stability in a range of 2. l to 9. 9. A possible exi' lana tion ntight be an 
interaction between the alcohol content of Polyenic M900 and the drug. 
Results sh01~ed heparin sodium to be without signs of incompati-
bility. Heparin solutions remained clear in all fluids throughout the 
study. Also, no appreciable pH changes occurred during this time. It 
appears that heparin is compatible with the Polyonic and Polysal series 
of solutions. However, Pritchard (53) published results in 1964 stating 
that the stability of heparin is reduced in solutions of pH below 6. 0. 
O'Riordan and MacGown (54) reported the best solutions for heparin 
infusion to be physiological saline and Hartmann's solution, stating that 
therapy was difficult to control using 5% dextrose in water as diluent. 
In a more recent report, Chessells (55) :repoTted that no difference in 
therapeutic effectiveness was seen between infusions of heparin in D-5-W 
89 
with a pH of 3.8 to 4.5 and 5% sorbitol with a neutral pH. 
Sodium bicarbonate proved to be physically comp~.tibl e in all 
solutions except Polyonic M900. All solutions remained clear and colorless 
cl.u:ring the t esting procedure. Sodium bicarbonate in Polyenic M900 
displayed effervescence . The pH of al l the solutions had been raised, 
\~hich was not unexpected . However, the pH of the Polyonic M900 with 
sodium bicarbonate was raised to pH 'l.l.-6.8 from pH 4.1 , a significant 
increase. The effervescence could be attributed to the interaction of 
hydrogen ions and bicarbonate . Sodium bicarbonate should be rated as 
incompatible with Polyonic M900. 
Vitamin B complex with C, in combination with the fluids tested 
showed no physical signs of incompatibility, and the pH remained stable 
in all admixtures . The test solutions were yellow due to the vitamin 13 
crn~lex with C, but all remained clear throughout the test. Little work 
has been done on stability of vitamin B complex with C in infusion fluids . 
Some work has been done on compatibility of the individual components 
however, such as vitamin C. Kassem (56, 57) published results of ascorbic 
acid stahility in various pH's and in the presence of metal ions . He 
concluded that stability of ascorbic acid was hi ghly dependent upon pH, 
with little stability in the lower pH range (2.5-4.5) and increasing to a 
maximum stability of pH 6 .5. Also , he stated that metal ions , such as 
copper, ferric, zinc, and magnesium, had de l eterious effects on ascorbic 
acid, although the effects of zinc and magnesium were insignificant . 
These results apply to ascorbic acid solutions alone, and not a combina-
tion of water solubl e vitamins. ConcentTation differences would be great 
comparing the solut ions used by Kassern and those obtained with 5 ml of 
vitamin !3 complex with C in a liter of balanced electrolyte fluid. 
90 
Comprehensive examination of the individual components of vitamin B com-
~ 
I 
plex with C was beyond the scope of this study. It does appear, hm~ever, 
that this vitamin combination is at least physically compatible in 
I combination with the fluids included here. 
Data obtained on the admixture of potassium chloride and the test 
solutions indicate that potassium chloride is compatible in all the 
solutions tested. No physical evidence exists which indicates precipita-
tion or color change occurred. pH values remained normal and constant 
throughout the test. These results were expected, as potassium chloride 
is a compound comprised of relatively un-reactive ions. 
The data compiled on admixture of hydrocortisone sodium succinate 
in the infusion fluids included here shows compatibility in all but 
Polyenic M900. A white milky precipitate was formed immediately upon 
admixture of the combination. Data on the other fluids indic1cte 
compatihili ty with no physical or spectrophotometric signs of incompati ~ 
bility and no pH changes during the 12 hour test period. 
Methylprednisolone sodium succinate, like hydrocortisone, 
appeared compatible in all but the Polyonic M900. Physical observation 
showed the admixtures to be clear and colorless except for the admixture 
with Polyenic M900, which demonstrated a milky white precipitate. No pH 
changes occurred in any of the fluids tested during the 12 hours. 
Spectral analysis shows that all the solutions, except the Polyenic M900 
admixture, produced the characteristic UV spectrogram, comparable to the 
standard. 
There was no visual evidence of an incompatibility between sodium 
pentobarbital and the electrolyte fluids, as the solutions remained clear 
and colorless for the duration of the test procedure. Also little 
91 
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' 
variation .in pH was noted throughout the time of examination. However, 
spectrophotometric analysis indicated pentobarbital to be incompatible in 
all but Polyonic Rl48. It may be that pentobarbital, with a relatively 
high pH of 10.5 (58) is incompatible with solutions of a low pH. 
Polyonic Rl48 has the highest pH (7. 2) of the fluids, and therefore, 
would be the only solution compa.tible with pentobarbital. 
Results of physical testing show potassium penicillin G to be 
compatible with the electrolyte fluids. All solutions remained clear and 
colorless, and the pH varied only slightly during the entire test pro-
cedure. Microbiological test results showed that penicillin G remained 
stable for the test periods in all solutions except Polyonic M900. In 
Polyonic M900, it shm~ed a significant decrease in activity, as evidenced 
by a decrease in zone size at the 12 hour interval. The degradation 
which occurred could possibly be due to two different factors of the 
Polyonic M900 solution; the low pH and the alcohol content. Although at 
one time alcohol was thought to inactivate penicillin, the most recent 
studies indicate that penicillin G is stable in alcoholic solutions (59, 
60). Most likely the low pH is responsible for the degradation seen at 
the 12 hour interval. A recent study by Im and Latiolais (44) indicated 
that penicillin G 1~as rapidly inactivated by solutions of acidic pH. 
Although the loss of activity of penicillin in Polysal D-10 M at the four 
hour interval appeared to be significant, in view of the data for the 12 
hour interval and the activity in similar solutions, it is felt that the 
loss may not be as great as it would appear. 
Ampicillin sodium appears to be compatible in all solutions except 
Polyonic M900. Physical rcsul ts show that all samples remained clear and 
coloTless during testing. The pH of the samples varied little over the 
12 hours, Nith the biggest chango occurring in Polysal (7.0 to 7.2 after 
12 hours). ~ILcrob.Lological results shm~cd that there \~ere no significant 
differences between the control samples and all solutions except for 
those prepared in Polyenic M900. The zones of inhibition produced by 
ampicillin in Polyenic M900 were significantly larger than the control 
samples at all time intervals. This may be accounted for by evidence in 
some of the mo.rc recent studies done on ampicillin stability (61-65). 
Ampicillin is the most acid stable of the synthetic penicillins, clue to 
its amino side chain group (61). Savello and Shangnnv (62) have lis ted 
the drug as being most stable at a pH of ·L!l3, 1~hich is the pH of the 
ampici llin-Polyonic M900 admixture (pH~4. 9) . Also, it ha~ been reported 
that ampic:Lllin b more stable in alcoholic solutions than in 11ater 
and/or dextrose solutions (61). Degradation of amp.icill:Ln decrea,;cs 1-!it:h 
an increase in the content of alcohol, clue to a decrease :i.n the 
dielectric con!.ltant. Based on tliC?. apparent lncrecise in activ:tty toJh.i.ch 
leads tt) a .,rating of incompatibl<.! ill this study~ li: ';vouJ.d seem that· 
Polyon:lc H900 might make the ideal infusion fluid to twe for admixture 
"ith ampl.e111in. Hm;ever, further studies on the -effect oE pll and alcohol 
on ampicill:ln must be done before this cmt be categorically utated. 
The tetracycline hydrochloride smnples remained clear throughout 
the test. 'fhe solutions did exhibit a yollo1·1 cohn', tlue to the formula-
tion of the product. The pll of the solutLons sho•.;c.J no 'lpprcciablo 
dtangc. f>.lic.rohit1logical results showed tcl:1·acycl ir:e tv be SUt~l!J .i.n all 
solutions except for Polyenic ~1900. A sienifi<~ant iti<'I'easc i.n zone of 
.inltibi.tiot) was 1\0tcd at ntl i11tcrvals. 1ft Polyorlit: :~14R, n sig11ifLcitnt 
decrease .i.n zone d.iamctcr h'as seen at the 12 hou~: intc.rviJ.l. ''"!'ho:-iD 
·incomp:ltibilltie~.; may be prcdictl.~d by cxc:nnin:i.ng the •;!:n.bi.lity l.'ll'vt'.i.le fvt· 
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tetracycline. Tetracycline solution is acidic in nature, with a pH range 
of 1.8 to 2.8. A pH profile study between the pH's of 3.4 to 7.5 showed 
instability in admixtures above pH 3. 4, with a band of greatest insta-
bility at pH 5. 0 (67). The Polyonic M900 solution provides tho low pH 
needed for tetracycline stability. Of the solutions included, Polyonic 
Rl48 has the highest pH, and therefore provided the most unstable medium 
for tetracycline. On the other hand, Polysal has similar pH but 
alteration in zone diameters remained insignificant. The reason for this 
difference cannot be explained. 
Cephalothin sodium remained compatible in all solutions throughout 
the testing procedure. Physical analysis shows that all solutions 
remained clear and colorless; again, the pH of the solutions varied 
little. Microbiological testing showed no significant difference in zone 
diameters with any of the solutions when compared to the standard. 
Cephalothin, having an optimum pH stability range of pH 4.0 to 7 .0, is 
reported to be stable in many types of infusion fluids (58). Instability 
might have been predicted in the low pH of the Polyonic M900 solution. 
However, this was not the case, as seen in the data. 
Cefazolin sodium proved to be stable in all solutions except 
Polyonic M900. All solutions were found to remain clear throughout the 
test procedure, and no significant difference in pH occurred during the 
12 hours. Microbiological results sh01ved no significant difference in 
zone diameters for any of the solutions except those prepared with 
Polyonic M900. Maximum solubility of cefazolin is in a pH range of 5.0 
to 6.0, while optimum chemical stability is between pH 5.0 and 7.0. At 
a lower pH, cefazolin is hydrolyzed (58). The low pH of Polyonic M900 
may have been the cause of the instability. 
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Carbenicillin disodium proved to be compatible in all solutions 
1 except Polyonic M900. Data obtained showed no change in physical 
\ 
characteristics and pH. H01;ever, microbiological tests did reveal a 
significant decrease in zone diameters of carbenicillin in Polyonic M900. 
' 
Carbenicillin has been reported to be inactivated in acidic media due to 
beta lac tam ring cleavage (68, 69). This could account for the de grad a-
tion seen with the Polyonic M900 admixture. Again, the effect of alcohol 
on carbenicillin has not been reported, and it is difficult to say 
whether the degradation of the Polyonic M900 admixture is due entirely 
to a low pH. 
Chapter 5 
SUMtviJ\RY AND CONCLUSIONS 
Tho purpose of this study was to de termine the compatibi lity 
char acteristics of a group of commonly used drugs in balanced e l ectrolyte 
solutions . Selected physical and chemical characteristics of the drugs 
were examined after their addition t o the individual electrolyte 
solutions . Physical characteristics cons isted of a visual observation 
for signs of color change, haze, or precipitate formation, and pH deter-
mination. Chemical compatibility was evaluated by ul travi olet 
spectl'os:::opy . The UV spectrum of the drug in solL~tion was obtained and 
examined fo r any l oss in absorbance, or any change i n the 1\ max. 
Significant a l teration would indicate a chemical lllcompatib.i.li ty . A 
microbiological assay was substi tuted for UV spectroscopy for the anti-
biotics . 
The drugs in combination with Po lysal , Po l ysal D-5 , Polysal D-5 M, 
and Pv l ys al D-lO M produced only one incompatibility as detected by lN 
spectrc~copy . Sodium pentobarbital displayed an altered spectram i n each 
of theso solution:;, due possibly to the p!-1 in~tabU:ity of sodium pento-
barbital . All other drugs r emained compatible in these solutions for at 
1 e<>~.t 12 r1ours . Sill1ilar results O(:Curred in the Polyenic series . In 
Po !.yorlic D·-5 R143, and Polyonic D -S MS6, only one d:wg , soclium pento-
barbital 1..-as incom1Jatible, possib ly due to pH ins t ability . The r emainder 
of the ch-ugs exhibited no incompatibilities in these fluid s during the 
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testing procedure. 
In Polyenic Rl48, only tetracycline hydrochloride appeared to be 
unstable, as evaluated by the methods utilized . It appeared, however, 
that pentobarbital was more stable in Polyenic Rl48 than in the other 
fluids, as evidenced by UV data. These results may be attributed to the 
comparatively high pH (7.2) of this fluid . 
Polyonic M900 exhibited the greatest number of incompatibilities 
in these series. Drugs which showed incompatibility in Polyonic M900 
included aminophylline, metaraminol bitartrate, sodium bicarbonate, 
hydrocortisone sodium succinate, methylpredniso lone sodium succinate, 
sodium pentobarbital, potassium penicillin G, te tracycline hydrochloride, 
carbenicillin disodium, and sodium cefazolin. In contrast, the admixture 
of ampicillin in Po lyonic M900 showed an appar8nt increase in activity, 
presumably due to the low pH and alcohol content . The incompatib.Uities 
exhibited were presumed to be caused by the l ow pH of Polyonic M900 . 
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